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The global objective of this research is to develop a synthetic biology toolkit 
consisting of molecules, cells, and devices that provide  flexible, yet selective targeting, 
sensing, and switching capabilities, that in turn guide  biological  behavior in user-
specified manner.  We employ bacteria as “smart” programmable devices.  We envision 
creating bacteria that autonomously move to specific areas, synthesize a drug, deliver the 
drug, and move on to new sites. “Targeting” endows bacterial cells the means to dock 
onto specific surfaces with antibody-antigen specificity. Sensing and switching capability 
allows bacteria to sense and, after making a “decision”, respond by synthesizing and 
delivering cargo to molecular scale features displayed on target surfaces.  Relevant 
surface features may include an overexpressed receptor on a tumor cell, glucagon-like 
 
 
peptide-1 receptor on pancreatic beta cells, or even other bacterial cells resident in a 
recalcitrant biofilm.  
Towards the realization of this goal, we employed an antibody-binding protein G 
display strategy to complex target-binding antibodies with bacteria.  We characterized the 
assembly and efficacy of this complex by binding to well-defined surfaces decorated with 
specific antigens.  For sensing and switching we made use of the genetic circuitry of 
bacterial quorum sensing (QS) that coordinates multicellular responses.  In particular, we 
hypothesized the creation of a biological “switch” that would take action only after a 
certain threshold “feature” density had been detected.  Specifically, in our most 
significant demonstration we designed and implemented QS based sensing and actuating 
based on the surface density of cancer-indicating EGFR receptors displayed on epithelial 
cancer cell lines.  
Because recent reports have demonstrated bacterial placement of a molecular 
“cargo” or “payload” in unrelated studies involving vaccination or direct attack on 
bacterial pathogens, we turned to developing innovative RNA-based drug syntheses 
concepts for eventual use in cancer therapy.  That is, we designed RNA interfering 
(RNAi) technology to arrest the progression of the eukaryotic cell cycle by silencing 
gateway genes that serve to guide cell division and proliferation.  Thus, our strategy 
serves to inhibit cell growth and promote cell death – actions that could find utility in 
treating metastatic cancer.  Through a different lens, this same concept, the molecularly 
“programmed” manipulation of cell cycle status and cell growth via synthetic biology can 
 
 
serve to promote recombinant protein production in an industrially relevant eukaryotic 
insect cell line. 
In summary, we envision the exploitation of bacterial cells as programmable 
smart devices that can target, dock and deliver cargoes that are synthesized and delivered 
only after a set of predetermined parameters are met.  We also envision a new biological 
“switch” that is based on the area-based density of a molecular feature – this will 
dramatically expand the capabilities and reach of synthetic biology.  Our concepts 
embrace the notion that the individual cell may be the product of synthetic biology, as 
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Chapter 1. Introduction 
 Motivation 1.1.
Synthetic biology is a revolutionary field where existing biological functionality 
is modulated and repurposed by rewiring genetic circuits, resulting in novel biological 
functionality[1-5].  It focuses on the fabrication of biomolecular syntheses and cellular 
capacities and provides a different perspective on traditional genetic engineering. 
Substantial progress has been achieved in many areas of research, including biomaterials 
synthesis, energy production, bio-computation, and biosensors [6-16].  Additionally, 
more and more studies have demonstrated the potential use of synthetic biology in 
biomedical applications such as vaccine development, tissue engineering, and 
therapeutics[17-24].  
Bacteria are considered one of the most important models for expediting the pace 
of synthetic biology progress due to their genetic accessibility.  Bacterial genomes are 
relatively simple, well-characterized, and easy to manipulate and amplify.  Besides, 
bacteria normally have fast growth rates, low maintenance costs, and, importantly, can 
produce products at high rates and yields (e.g., recombinant proteins can constitute more 
than 20% of the total cellular protein.  This is one of the reasons bacteria are widely used 
in industrial fermentation and recombinant protein production processes) [25-27].  
One somewhat controversial but emerging research area in synthetic biology is 
the use of microbes as disease or cancer fighting devices[28-30].  Historically, the 
potential for bacteria to serve as anticancer agents was discovered 150 years ago by 
German physicians, W. Busch and F. Fehleisen.  They reported the regression of tumors 
of patients after accidental skin infections (erysipelas) caused by Streptococcus 
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pyogenes[31].  More recently, researchers have shown that tumor specific 
microenvironments present a preferred habitat for bacteria such as Clostridium, 
Salmonella, and Escherichia as compared to healthy tissue [32-34].  The conditions of 
oxygen-deprivation, chaotic vasculature, heightened metabolic byproducts, and localized 
inflammation associated with tumor growth that sometimes present challenges to 
traditional radiotherapy and chemotherapy are, in fact, ripe environments for directed 
anaerobic bacterial growth [35-40].  By exploiting natural bacterial capabilities, a 
synthetic biology approach could be used to enhance targeting specificity, tumor-killing 
activity, and a reduction of toxicity.  In a 2010 review[41], Forbes summarized recent 
advances and conceptualized a model of “smart” bacteria for future therapies.  He 
proposed an ideal “robot factory” (Figure 1-1a) that could perform important functions: 
target tumours, self-propel, produce cytotoxic molecules in response to triggering signals, 
and produce externally detectable signals.  In parallel to the robot factory, bacteria 
(Figure 1-1b) could be engineered to carry out similar duties: steer toward 
chemoattractants by the control of flagella (blue), produce anticancer proteins (dark blue) 
in response to molecular signals (red squares), and produce detectable biomolecules (red).  
Through the careful tuning of bacterial phenotypes, Forbes envisioned a future of 
“perfect” bacteria for cancer therapies.     
In part motivated by this potential, we had been pursuing parallel concepts by 
engineering targeting and “switching” capabilities into bacteria.  Specifically, we created 
a targeting capability for E. coli by displaying Streptococcal antibody-binding protein G 
on the outer surface of E. coli which mediates antibody-antigen interactions on the 
surface of selected bacteria.  In a certain sense, such a strategy iterates monoclonal 
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antibody blocking therapies, with an additional self-induction mechanism for further 
therapeutic use.  The new targeting module allows bacteria to “dock” with specific 
surfaces of interest.  Additionally, we conceived of a biological “switch” that was not 
envisioned by Forbes [41] in which only cells with a sufficiently up -regulated density of 
cancer-identifying surface receptors would be actuated upon.  That is, we developed an 
innovative “switching” feature by leveraging the communication process of bacteria 
known as quorum sensing that guides multicellularity at “threshold” cell numbers.  This 
creates a localized community based decision-making function that is autonomous, 
eliminating a need for intervention by external signals.  Both new modules will 
potentially benefit the development of bacterial cancer therapies.  Lastly, an RNA 
interference (RNAi) approach was used to arrest cell cycle progression, hindering 
eukaryotic cell growth, metabolically altering the cell physiology.  We demonstrate by 
increasing recombinant protein productivity in a commercially relevant cell line.  
Conveniently, we have previously demonstrated that a sufficiently significant “dose” of 
the identical RNAi molecule (that targets cyclin E) can arrest and kill cells – revealing its 
potential as an anti-cancer candidate for tumor regression.     
In this dissertation, we describe the component parts needed to develop this 
strategy.  While the concepts are easily grasped, there existed few experimental 
approaches or platforms upon which to construct and test these concepts.  We organize 
the dissertation in sections.  We will briefly introduce the principles and technologies 
necessary for generating the synthetic biology modules in the latter part of Chapter one as 
research background.  The antibody assembly strategy, which is created and tested via 
“biofabrication” will be discussed in Chapter two.  The rewiring of bacteria for 
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empowering synthetic switching capability will be described in Chapter three.  The 
metabolic engineering of eukaryotic insect cells using RNAi (payload) will be described 
in Chapter four.  Again, this is an example for both anti-cancer therapy and bioprocess 
innovation.  Finally, a summary and a description of future work are provided as Chapter 









Figure 1-1  Bacteria as the optimal robot factory cancer therapies. (a) The perfect cancer 
therapy could be imagined as a ‘robot factory’ that could carry out six important 
functions: target tumours, produce cytotoxic molecules, self-propel, respond to triggering 
signals, sense the local environment and produce externally detectable signals. (b) 
Bacteria have biological mechanisms to carry out these functions: gene translation 
machinery to produce anticancer proteins (dark blue); flagella to chemotax (blue); 
specific gene promoter regions to respond to molecular signals (red squares); and 










 Research background – “Biofabrication” –and “Synthetic Biology” 1.2.
In nature, biology employs a bottom-up means to assemble biomolecules or 
fabricate structures, which contrasts starkly the top-to-bottom manufacturing processes 
traditionally used in industry.  The exploitation and repurposing of these bottom-up 
biological fabrication processes is defined as biofabrication.  It includes the uses of cells 
or other biologics as the basic building blocks in which biological models, systems, 
devices and products are manufactured [42-44].   
Synthetic biology [1-5], defined as a way to design and construct new biological 
parts or functions by rearranging genomes, could be considered an upstream supply line 
to biofabrication processes.  In conjugation with biofabrication, the new biological 
products synthesized from synthetic biology could be fed into downstream applications.   
In this chapter, we combine both synthetic biology and biofabrication to create new 
biological switches that provide for targeting, docking, motility and payload synthesis as 
well as facilitate bacterial targeting by creating testing environments and assembly 
strategies based on biological means and components, respectively.  The detailed 
concepts, terms, and definitions of system components are described below that when 
pulled together portray the potential for innovative anti-cancer therapy. 
 
 Biofabricated devices and assembly 1.2.1.
Protein G is an immunoglobulin-binding protein expressed in Streptococcal 
bacteria, which selectively binds the antibody’s constant (Fc) region and allows the Fab 
region to be active and accessible to antigens.  It has been widely used in the fields of 
antibody purification and molecular diagnostics[45].   
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By repurposing protein G, we could not only orient and assemble the antibodies 
on a specific surface but also tether them to a supramolecular structure (i.e., the cell 
membrane) through biofabrication [46-48].   
In Chapter two, we describe a novel antibody orientation strategy based on the 
covalent capture and display of protein G.  This enables the hierarchical assembly of 
antibodies onto a specific biopolymer surface, chitosan, and facilitates the 
characterization of antibody assembly and antigen detection on devices and cells.  That is, 
this protein G biofabrication method will be further exploited in Chapter three for 
tethering antibodies onto a bacterial outer membrane, enabling a flexible targeting 
functionality.  This “prescribable” targeting increases the range of applications for these 
bacteria.   
 
 Enabling the switching capability: Rewiring quorum sensing circuitry for 1.2.2.
synchronizing multicellular phenotype 
Quorum sensing (QS) is a microbial cell-to-cell communication process mediated 
through secreted signaling molecules that coordinate unicellular properties, guiding 
multicellular behavior [49, 50].  This is prevalent in phenotypes such as pathogenicity, 
biofilm formation, and virulence.  In order to develop strategies against quorum sensing, 
its genetic regulatory structures and pathways for synthesis and signal transduction have 
been extensively studied with molecular resolution [51].  Recently, QS circuitry has been 
rewired for applications in synthetic biology, including switches, sensor devices, and 
recombinant protein production applications [52-54].  In this study, we linked the LuxS 
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quorum sensing machinery controlled by the signaling molecule autoinducer-2 (AI-2) 
from E. coli directly by creating a switching module or cassette.   
A brief description of the LuxS QS circuitry follows (Figure 1-2) [54].  AI-2 
based signaling is generated and processed by the lsr operon. AI-2 production is mediated 
by two enzymes: Pfs (nucleosidease) and LuxS (AI-2 synthase).  First, the precursor S-
adenosylhomomcycteine (SAH), which is the intermediate metabolite from biosynthesis 
or modification of DNA, RNA and proteins, is converted  to S-ribosylhomocysteine 
(SRH) by Pfs. SRH is then catalyzed into 4,5-dihydroxy-2,3-pentanedione(DPD) by 
LuxS.  The resulting DPD is spontaneously cyclized into the signaling molecule AI-2. 
Initially, AI-2 accumulates extracellularly during the low density phase of bacterial 
growth (early growth phase).  Thereafter, AI-2 is imported back into cells by the Lsr 
ABC-type transporter when cell density reaches a putative threshold (near early 
stationary phase).  Intracellular AI-2 is then phosphorylated by LsrK kinase and the 
resultant phospho-AI-2 activates further expression of Lsr components by binding and 
releasing LsrR (the repressor of the lsr operon) from the DNA.  This combined negative 
and positive feedback of AI-2 mediated QS results in the tight regulation of the 
multicellular switch.  By harnessing and further amplifying the QS switch-like signal, the 
bacteria can decide whether or not to turn on gene expression “smartly” by evaluating the 





   
 
 




Figure 1-2  AI-2 mediated QS communication. The signal generation, uptake, and 
derepression of lsr operon in E. coli. AI-2 (green sphere) is produced from S-
adenosylhomocysteine (SAH) by Pfs and LuxS and accumulates extracellularly with low 
cell density. AI-2 is internalized by the Lsr transporter followed by phosphorylation via 
kinase, LsrK. Phospho-AI-2 (green sphere-P) de-represses both the lsr and lsrRK 
promoters. [54]  
 
 
 Eukaryotic insect cell cycle and proliferation control using RNAi : Cell cycle 1.2.3.
arrest as an anti-cancer strategy  
1.2.3.1. Cell cycle 
The eukaryotic cell cycle consists of both the machinery that governs cell division 
in all its stepwise facets and the cell division itself.  As such, it plays a crucial role in 
embryonic development and differentiation, cell death or apoptosis, DNA repair, 
angiogenesis, and tumorigenesis [55-62].  Researchers have also found that that cell cycle 
and cell proliferation status are closely related to the activity of protein synthesis 
machinery [63] and as such, have targeted the cell cycle as a tool for altering the 
metabolic landscape for product synthesis.  As indicated in Figure 1-3, the cell cycle can 
be divided into four distinct phases: G1 phase, S phase, G2 phase and M phase (mitosis).  
S and M phases represent DNA synthesis and mitosis phases respectively, and phases in 
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between are G1 (“gap-1”) and G2 (“gap-2”) phases. Not only acting as “gaps”, the 
biosynthetic activities of proteins and enzymes are highly active in G1 and G2 phases 









Figure 1-3  Simple representations of the cell cycle. A typical (somatic) cell cycle can be 
divided into four sequential phases: G1 (gap-1), S (DNA replication), G2 (gap-1), and M 





RNA interference (RNAi) is a cellular process that inhibits gene expression by 
degrading specific RNA species resulting in selective gene silencing.  RNAi was initially 
found in plants as a means for viral defense.  The use of antisense RNA to interfere with 
gene activity in C. elegans was first utilized by Guo and Kemphues (1995) to study par-1 
function [65].  Subsequently dsRNA, formed by the annealing of sense and anti-sense 
strands, was discovered and used by Fire et al. 1998 [66], who subsequently won the 
Nobel prize.  As presented in Figure 1-4, dsRNA mediated gene silencing results from 
the cleavage of long dsRNA by Dicer (RNAse III) into 21-25 small interfering RNA 
(siRNA).  These siRNAs then associate with RNA-induced silencing complex (RISC) 
through which they are processed to become single-stranded RNA that guide the RISC 
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complex to target mRNA.  Degradation and silencing of specific mRNA species is the 
consequence.  Due to this ability to knockdown or silence gene expression, RNAi has 
become a common and convenient tool in studies of gene function and has been widely 
used in developmental biology [67], medicine [68], functional proteomics[69-71] as well 











Figure 1-4  RNA interference pathway. dsRNA is cleaved into siRNAs by dicer and the 
resultant siRNAs associate with RISC. Unwinding of siRNA results in target mRNA 




In Chapter four, RNAi is used to silence a novel insect cell line homologue of the 
positive cell cycle G1 regulator, Cyclin E.  This knockdown resulted in cell cycle arrest at 
the G1 phase, decreasing cell growth and enhancing recombinant production synthesis, a 
useful outcome from a metabolic engineering perspective.  
This result also concerns cancer biology, since defective cell cycle regulation is a 
common attribute of oncogenic phenotypes [75].  As previously described, the cell cycle 
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consists of important machinery for cell division and proliferation in eukaryotic cells, 
ensuring daughter cell integrity and survivability.  Cancer cells that have escaped from 
the cell cycle reproduce abnormal cells rapidly and form tumors due to unchecked growth.  
Re-activation of cell cycle regulation by arresting the cancer cells using RNAi is 














Chapter 2. Biofabrication of antibodies and antigens 
via IgG-binding domain engineered with activatable 
pentatyrosine pro-tag 
 
 Introduction  2.1.
Antibodies are biological recognition elements extensively used for laboratory-
based immunoanalysis [76-78].  Antibodies are also integral to immuno-affinity-
chromatography for the purification and separation of proteins [79, 80].  Efforts to extend 
the use of antibodies within sensors and devices have attempted to ensure the proper 
orientation of their antigen-binding sites [81-86].  That is, it is well recognized that the 
various antibody assembly techniques can lead to reduced antigen binding capacity (via 
steric hindrance, denaturation, chemical modification [48, 87].  In nature, antibodies can 
be oriented, for example, at cell surfaces by binding to membrane-bound proteins that 
selectively bind the antibody’s constant (Fc) region.  Not only do these binding proteins 
orient the antibodies, but they also tether them to a supramolecular structure (i.e., the cell 
membrane).  Using lessons from nature, we employ three biologically-based methods for 
the hierarchical assembly of antibodies into macroscopic systems [46]. 
Specifically, in this work, we make use of immunoglobulin (Ig) binding proteins 
derived from the cell surfaces of bacteria.  These proteins selectively bind the antibody’s 
constant (Fc) region and free the antigen-binding (Fab) site to interact with antigens [48, 
88-90].  We have genetically modified a Streptococcal IgG binding domain (derived 
from protein G) to serve as a scaffold for the generic assembly of antibodies onto a 
variety of surfaces.  Namely, we have incorporated a tyrosine rich ‘‘pro-tag’’ at the C-
terminus of protein G [91, 92].  These tyrosyl residues are enzymatically activated by 
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tyrosinase to quinones, which then covalently couple to the primary amines of pH-stimuli 
responsive polysaccharide chitosan [93-96].   
Our approach, outlined in Figure 2-1, builds upon nature’s methods to orient 
antibodies onto supramolecular structures. Self-assembly is employed to bind antibodies 
to the engineered protein G.  As noted, Protein G was engineered for enzymatic-assembly 
by genetically fusing a C-terminal (tyr)5 pro-tag that can be selectively activated by 
tyrosinase for covalent conjugation to the aminopolysaccharide chitosan.  Assembly from 
the nano- to the macro-scale is achieved by the directed-assembly of chitosan in response 
to external stimuli[97].  Central to this ‘‘biofabrication’’ approach are: (1) the pH 
dependent solubility characteristics of chitosan, shown previously to enable pH-based 
‘‘switching’’ of the solubility of a chitosan-conjugated protein, and (2) the enzymatic 
activation of a protein G Fc-binding domain shown here for the first time. 
Of note, the protein G used in this study was originally engineered to be a fusion 
with three repeats of the antibodybinding domain and 72 repeats of the pentapeptide 
derived from the hydrophobic domain of elastin (designated E72G3) [47].  Protein G 
fusions with elastin adhere non-covalently to hydrophobic surfaces [47, 98].  We 
modified E72G3 by deleting the elastin repeats, adding a pentatyrosine sequence to the 
C-terminus, and expressing the protein from a plasmid within E. coli that adds an N-
terminal histidine tag to yield the protein HG3T [99].  This facilitates coupling of protein 
G to chitosan, and further, assembly of the protein G, antibodies, and antigens into three 
model device formats (96-well microtiter plates, microfabricated chips, and a fiber mesh). 

























Figure 2-1  Schematic of three biofabrication methods used for hierarchical assembly 
(not to scale).  At the nanoscale, antibody binds to the Streptococcal protein G while the 
protag fused to protein G allows its enzyme-mediated conjugation to the 
aminopolysaccharide chitosan.  The stimuli-responsive network-forming properties of 
chitosan allow assembly at the micro- and macro-scales.  Hierarchical assembly is 
suggested for three formats; conventional multiwell plates, electrode addresses within 











 Materials and methods 2.2.
Antigens and Antibodies 
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Two fluorescent antigens were used in this study, Texas-red labeled bovine serum 
albumin (BSA; Invitrogen) and green fluorescent protein (GFP).  GFP was expressed 
from E. coli BL21 and purified using standard methods [100].  Five alkaline-
phosphatase-linked antibodies were used in this study; goat anti-guinea pig (Kirkegaard 
and Perry Laboratories), goat anti-mouse (Sigma), goat anti-rabbit (Sigma), rabbit anti-
chicken (Sigma) and rabbit anti-goat (Sigma).  Two fluorescently-labeled antibodies were 
used; FITC-labeled goat anti-mouse (Sigma) and Texas red-labeled goat anti-rabbit 
(Rockland Immunochemicals).  Two antibodies were used to study antigen binding, goat 
anti-GFP (Rockland Immunochemicals) and goat anti-BSA (Sigma). 
 
Vector Construction and Fusion Protein (HG3T) Expression 
As partially described in Shi et al. 2008, we PCR-amplified the 3 repeats of the 
Streptococcus protein G Fc-binding domain (designated as G3) from the template vector 
pET32-E72G3 which, in turn, has the G3 domain fused to 72 repeats of the pentapeptide 
(E72) from the hydrophobic domain of elastin [47].  PCR primers within the reaction 
contained an extra sequence at the 3’ end that codes for the pentatyrosine protag 
(designated as T).  The resulting PCR product (G3T) was ligated into a blunt II-TOPO 
vector and then transformed into TOP10 E. coli cells for pTOPO-G3T amplification.  The 
G3T DNA fragment excised from pTOPO-G3T by EcoRI and NcoI was inserted into a 
pET32 vector that codes for an N-terminal histidine tag.  The protein product expressed 
from the pET32-G3T plasmid is designated HG3T.  The pET32-HG3T vector was 
transformed into E. coli BL21(DE3) for protein expression.  The cells were inoculated 
into LB medium with ampicillin (100 μg/ml) and grown 16 hours at 37oC and 250 rpm 
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shaking.  These cells were transferred into fresh LB media (1% inoculation ratio), grown 
to an OD600 of 0.5, and induced by adding IPTG (1 mM final concentration).  The 
induced cell culture was transferred to a 30oC w/ shaking environment and incubated for 
4-6 hours.  The cells were then collected by centrifugation and lysed using Bugbuster 
reagent (Novagen).  The supernatant was separated from cell debris by centrifugation and 
recombinant proteins were purified by Talon metal affinity resins (Clontech).  The final 
HG3T product was desalted by dialysis.    
  
 Protein Analysis using LabChip    
Cell extracts and purified HG3T proteins were analyzed using 2100 Bioanalyzer 
(Agilent Technologies).  First, the protein samples were mixed with the denaturing 
solution (Agilent Protein 230 Kit) and heated for five minutes.  After cooling, samples 
were loaded into the pre-cast protein chip.  Molecular weights of each major component 
in the cell lysate and HG3T samples were determined by the Bioanalyzer.  Bovine serum 
albumin (BSA, New England Biolabs) with M.W. ~66.43KDa was used as a control.  
 
Western Blots   
Protein HG3T was mixed with sampling buffer and then heated to 95oC for ten 
minutes.  Samples were then loaded into multiple wells and run on a 12.5% SDS-PAGE 
gel at 150 volts for 1 hour.  Protein was then transferred to nitrocellulose membranes by a 
BioRad Trans-Blot semi-dry transfer cell with BSN transfer buffer (48 mM Tris, 39 mM 
glycine, 20% v/v methanol, 0.0375% w/v SDS) and a voltage of 15 volts for 20 minutes 
and then 20 volts for 20 minutes.  The nitrocellulose membrane was then washed 3 times 
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with TBS (20mM Tris-HCl, pH 7.5, 500 mM NaCl), blocked with 5% (w/v) nonfat dry 
milk in TBS for two hours, and washed 3 times with Tween-containing TBS (0.05% v/v 
Tween 20).  The nitrocellulose membranes containing HG3T were then cut into pieces 
and incubated for 1 hour with different enzyme-linked antibodies that had been diluted in 
TBS buffer containing Tween 20 (0.05 %) and nonfat dry milk (1 %).  The antibodies 
were from 2 separate hosts (rabbit and goat) and were linked with alkaline phosphatase 
(AP).  After washing the membrane pieces 3 times with Tween-containing TBS and then 
TBS, the membranes were developed by adding the indolyl phosphate substrate solution 
and incubating for several minutes.  The substrate solution was prepared by diluting 
commercially-available NBT/BCIP substrate (Roche) with Tris-HCl buffer (0.1 M, pH 
9.5) containing NaCl (0.1 M,) and MgCl2 (0.05 M).   
 
Tyrosinase Activation of HG3T and Conjugation to Chitosan 
Various amount of protein HG3T was added in wells of 96 well plate and each 
was mixed with tyrosinase (350U). 100 nmoles of o-phenylenediamine (OPD; Sigma) 
was added in each of the reacting well to final volume of each well 200 ul.  The positive 
control using catechol (Sigma) was conducted with equivalent amount to protein HG3T.   
Absorbance of the reaction product was detected by plate reader at the wavelength of 
450nm.  For chitosan conjugation studies, chitosan films were first cast on the bottom of 
each well of a 96-well plate by pipetting a chitosan solution (0.5 w/v % pH 4.8) into the 
well, drying overnight at 45 °C, neutralizing with NaOH (1 M) for 30 minutes, and 
washing three times with 0.01 M PBS.  The reactions were performed in the chitosan-
casted wells by the combination of HG3T (0.72 nmoles), E72G3 (0.72 nmoles), and 
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tyrosinase (350 units) to final volume of 200 ul.  The solutions were incubated for 2 
hours and after which the solutions were pipetted into a cuvette and the UV-Vis spectrum 
was measured.  
 
Multiwell plate studies    
Enzymatic assembly of protein HG3T was performed by adding tyrosinase (100 
U/ml) and the (tyr)5-tagged protein G (HG3T) to each chitosan-coated well (the amount 
of HG3T was varied) and incubating overnight at room temperature in an orbital shaker.  
After enzymatic assembly, the wells were rinsed three times with PBS and incubated with 
NaBH4 (0.2% w/v in PBS) for 15 minutes.  After assembling HG3T, the plate was 
washed three times with PBS, incubated for 2 hours with a blocking solution (5 % w/v 
nonfat milk in 0.01 M PBS), and rinsed three times with tween-containing PBS (TPBS; 
0.05% v/v Tween 20 in PBS).  Antibodies were then and diluted in TPBS containing 1% 
nonfat milk.  Antibodies were assembled in each well by adding the diluted antibody 
solutions and incubating for 1 hour.  After antibody assembly, the plate was washed three 
times with TPBS and then rinsed with PBS.  When alkaline-phosphatase (AP) linked 
antibody was studied, the wells were first rinsed with a solution containing 
diethanolamine (DEA; 0.1 M), and then incubated for 30 minutes with the substrate 
solution containing p-nitrophenylphosphate (pNPP; 0.1% w/v) plus DEA (0.1 M).  For 
antigen-binding studies, the GFP antigen was diluted in PBS and incubated for one hour 
in wells containing the anti-GFP antibody (goat anti-GFP) after which the wells were 
washed three times with TPBS.  Plate readers were used to measure either absorbance or 
fluorescence in studies with 96-well plates.  Absorbance was used to measure products 
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generated from reactions of the AP-linked antibody (405 nm).  Fluorescence was used to 
measure binding of FITC-labeled antibodies (excitation filter 494 nm, emission 521nm) 
and GFP (excitation filter 395 nm, emission 509 nm).  
 
Chip studies   
Chitosan was electrodeposited onto the left electrode by partially immersing the 
chip in a chitosan solution (0.8 w/v %, pH 5.5) and applying a negative voltage to left 
lead.  Deposition was performed for 1 minute at a constant current density of 3 A/m2 
(typically the applied voltage was 2-3 volts).  After deposition, the chips were 
disconnected from the power supply, removed from the deposition bath, and rinsed with 
water and then twice with PBS buffer (pH 7.4).  HG3T was enzymatically-assembled to 
the electrodeposited chitosan film by incubating the chip overnight in 2 ml solution 
containing tyrosinase (100 U/ml) and HG3T (0.8 uM), after which it was incubated for 15 
minutes with NaBH4 (0.2% w/v in PBS).  After HG3T assembly, the chips were rinsed, 
immersed in a milk blocking solution (5 % nonfat milk in PBS) for 2 hours and then 
rinsed three times with TPBS.  Antibody was then assembled by incubating the chip for 1 
hour in 2 ml of anti-GFP antibody solutions (0.3 uM diluted in 1% milk TPBS solution).  
Antigen binding was then achieved by immersing the chip in a 2 ml solution containing 
the GFP antigen and incubating for 1 hour after which the chips were washed with PBS.  
Fluorescence images of chips were obtained with a Leica fluorescence microscope using 
the following filter sets; FITC-labeled antibody (excitation 480/40 nm, emission 510 nm), 
GFP (excitation 425/60 nm, emission 480 nm), and Texas-red-labeled BSA (excitation 
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560/55 nm, emission 645/75 nm).  Fluorescence photomicrographs were then analyzed 
using ImageJ software (National Institutes of Health). 
 
Fiber studies   
Chitosan fibers were prepared by injecting a chitosan solution (1.6 w/v %, pH = 
5.0) through a 27 gauge needle into an aqueous solution containing 20 % ethanol and 1 M 
NaOH, and allowing the fibers to incubate in this bath for 10 minutes.  The resulting 
fibers were rinsed with PBS, and the HG3T protein was assembled by contacting the 
fibers overnight with a solution of HG3T (0.8 uM) and tyrosinase (100 U/ml), and then 
incubating the fibers for 15 minutes with NaBH4 (0.2% w/v in PBS).  After enzymatic 
assembly of HG3T, the fibers were blocked (5 % nonfat milk in PBS).  For antibody 
assembly, the HG3T-conjugated fibers were incubated for 1 hour with 2 ml of either anti-
GFP antibody (0.3 uM) or anti-BSA antibody (0.1 uM).  In initial experiments, the anti-
GFP fibers were incubated for 1 hour with the GFP antigen (0.17 uM).  In later studies, a 
loose fiber mesh was created from both the anti-GFP presenting and the anti-BSA 
presenting fibers, and this mesh was incubated for 1 hour with an antigen mixture 
containing GFP (0.17 uM) and Texas-red-labeled BSA (0.08 uM).  Fluorescence images 





 Results and discussion 2.3.
Expression and Characterization of HG3T Scaffold 
Figure 2-2a depicts the resultant expression sequences within pET32-HG3T for 
HG3T synthesis in E. coli.  In Figure 2-2b, the estimated M.W. of BSA is ~66KDa which 
is consistent with its known molecular weight.  The purified protein migrates within the 
SDS-PAGE at ∼43KDa, also consistent with its predicted value (~40 KDa).  
Immunoblots for antibody capture (Figure 2-2c) indicate that the engineered protein G 
(HG3T) can bind many different antibodies derived from both rabbit and goat.  Hence, 
the HG3T scaffold is of general utility for the assembly of antibodies.  We note the 
protein G used in this study (HG3T) was originally engineered as a fusion with three 
repeats of the antibody-binding domain and 72 repeats of the pentapeptide derived from 
the hydrophobic domain of elastin (designated E72G3).  In experiments not shown, we 
added HG3T, E72G3, and GFP (control) to individual wells, performed SDS-PAGE and 
Western blots using alkaline phosphatase-linked antibody (anti-goat).  We found 
comparable binding of antibody to HG3T and E72G3 (and none to the GFP control).   
Hence, we believe the C-terminal pentatyrosine fusion tag does not adversely affect 
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Figure 2-2  Protein G (HG3T) expression and activity characterization. (a) Vector 
pET32-HG3T was constructed by deleting elastin domain and adding pentatyrosine tag 
(Tyr5) from the original pET32-E72G3 vector. (b) SDS-PAGE result of purified protein 
HG3T indicating molecular weight ~43KDa comparable to the theoretical M.W. ~40KDa. 
(c)  Antibody binding activity of HG3T was shown in western blots using various 
antibodies as indicated. 
 
 
Activation of the engineered protein G (HG3T) by tyrosinase was investigated for 
the first time using o-phenylenediamine (OPD).  Chemical analysis of the pentatyrosine 
tag activation was not shown previously [101], its use here suggests single residue 
activation by tyrosinase.  As illustrated in Figure 2-3a, OPD reacts with o-quinones to 
generate a phenazine complex that absorbs at 450 nm[102, 103].  When HG3T is 
incubated with tyrosinase and OPD, there is a large increase in absorbance as shown in 
Figure 2-3b.  Controls lacking tyrosinase or HG3T (i.e., the y-intercept in Figure 2-3b) 
show no absorbance increases, while the control lacking OPD shows small absorbance 
increases consistent with tyrosinase-mediated browning reactions.  These results indicate 
that tyrosinase activates HG3T by converting tyrosine residues into reactive o-quinone 
residues.  To provide a preliminary estimate of the number of tyrosine residues activated 
by tyrosinase, we incubated the small-molecule chemically-active analogue, catechol, 
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with tyrosinase and OPD, and measured the absorbance increase.  Catechol was 
incubated with OPD and tyrosinase at the identical molar concentration as HG3T.  
Catechol, which contains a singular reactive site and resultant o-quinone, was observed to 
absorb 450 nm light nearly identically to HG3T as a function of OPD concentration 
(Figure 2-3b).  The nearly identical slopes in these curves along with similar absolute 
absorbance suggest that the functional dependence of the reaction with OPD is the same 
between the two reactions.  Because there is one reactive site within catechol, these 
results support the notion that tyrosinase oxidizes one tyrosine residue per HG3T protein.  
We further note there was no absorbance increase when the E72G3 protein (no tyrosine 
tag) was incubated with tyrosinase and OPD.  
In our previous work introducing the tyrosine pro-tag concept [92, 93], we 
demonstrated the coupling of GFP to chitosan.  Additionally, two bacterial enzymes, Pfs 
and LuxS, have been enzymatically conjugated to chitosan [104, 105].  Evidence that the 
tyrosinase-activated HG3T protein can be conjugated to chitosan is provided in Figure 2-
3c.  In this experiment, cast chitosan films were incubated with tyrosinase and HG3T, 
and these films were observed to have large increases in absorbance at wavelengths 
above 350 nm.  Control films incubated without tyrosinase or HG3T show little 
absorbance above 350 nm, and films incubated with the E72G3 protein plus tyrosinase 
also show no absorbance above 350 nm.  Increased UV-Vis (300nm-700nm) absorbance 
provides evidence for quinone-mediated reactions [101, 106].  The results in Figure 2-3c 
are consistent with those in Figure 2-3b and indicate that tyrosinase can selectively 




Figure 2-3  Enzymatic activation of (tyr)5-tagged protein G (HG3T) and conjugation to 
chitosan.  (a) The reaction schematic of the tyrosinase activation of HG3T and 
conjugation to chitosan.  (b) Tyrosinase-mediated activation is observed using OPD to 
generate the phenazine chromophore.  Similarities in the curves for the experimental 
samples (HG3T + Tyrase + OPD) and controls using the small molecule analogue 
catechol (Cat) suggest one tyrosine residue is activated per HG3T protein.  The failure of 
tyrosinase to activate E72G3 indicates that activation requires the tyrosine residues of the 
protag.  (c) Conjugation of the HG3T protein to chitosan was studied by incubating 
chitosan films with components and measuring the absorbance increase of the film.  





Biofabrication of Antibody/Antigen Assemblies 
The methods described in the next sections demonstrate biological means to 
fabricate biomolecular complexes that preserve biological function of their component 
parts. We have refered to this process as “biofabrication” [46].  
 
Multiwell plate format 
To test the function of the protein G-mediated assembly of antibodies, we 
fabricated the equivalent of an ELISA.  Chitosan films were cast on the bottom of each 
well, HG3T was enzymatically-assembled onto these films using tyrosinase, antibody 
was allowed to self-assemble to this surface-bound protein G by incubation for 2 hours.   
In our first study, we used an alkaline phosphatase-linked antibody (rabbit anti-goat) and 
measured antibody binding by incubating with the AP-substrate.  As shown in Figure 2-
4a, the absorbance associated with the AP-reaction increases monotonically with HG3T.   
Considerably less absorbance is observed for the control in which tyrosinase was deleted 
from the HG3T assembly step.  Antibody binding to the assembled HG3T was confirmed 
in a second multiwell plate experiment using fluorescently-labeled antibody (FITC-
labeled goat anti-mouse antibody).  Figure 2-4b shows increased fluorescence intensity 
with increasing concentration of HG3T.  A final study using the multiwell plate format 
was performed to demonstrate that the assembled antibody retains antigen-binding ability.   
Specifically, we generated an antibody-HG3T-chitosan assembly using antibody for the 
green fluorescent protein (goat anti-GFP antibody).  Figure 2-4c shows saturation 
behavior for binding of the antigen GFP to this assembly.  The results in Fig 2-4 confirm 
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that HG3T that is conjugated to chitosan can quantitatively assemble antibodies that can 





Figure 2-4  Antibody assembly and antigen binding using conventional 96-well plates 
with cast chitosan and HG3T assembled in each well.  Antibody assembly was confirmed 
using; (a) alkaline phosphatase-linked rabbit anti-goat antibody (0.4 uM) with the pNPP 
substrate, and (b) FITC-labeled goat anti-mouse antibody (2 uM). (c) Antigen binding 




Chitosan’s pH-responsive network-forming properties offer unique opportunities 
for extending antibody-based analysis from conventional multiwell plate formats to lab-
on-a-chip devices[46].  Chitosan can be induced to undergo a localized sol-gel transition 
in response to a pH gradient established at a cathode surface[107-109].  After rinsing, an 
electrodeposited chitosan film is stable in the absence of an applied voltage where the pH 
is retained above about 6.5 (chitosan re-dissolves at low pH).  Properties of the 
electrodeposited chitosan (e.g. thin film, matrix, or hydrogel) depend on the deposition 
characteristics [110].  To test whether electrodeposited spatially-resolved chitosan films 
allow antibody assembly we used the chips shown in Figure 2-5a.  Chitosan was 
electrodeposited onto the left electrodes of these chips and then HG3T was 
enzymatically-assembled onto the electrodeposited chitosan (e.g. Figure 2-4).  Next, the 
chips were incubated with a fluorescently-labeled antibody (FITC-labeled goat anti-
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mouse antibody).  Figure 2-5a depicts the loading of antibody onto the chitosan varies 
with the concentration of antibody in the incubation mixture.  There was a linear 
relationhip between the electrode’s fluorescence and the antibody concentration.  These 
results demonstrate that chitosan’s electrodeposition retains its reactivity for tyrosinase-
mediated conjugation and antibodies can be quantitatively assembled using the protein G 
scaffold.  
To test antigen assembly onto the antibodies, we electrodeposited chitosan, 
enzymatically-assembled HG3T to the left electrodes (Fig 2-5b), and then assembled an 
anti-GFP antibody.  Chips were then incubated with various amounts of GFP antigen.  
The fluorescence images show GFP is assembled onto the left electrode with high spatial 
selectivity, while the plot shows a semi-quantitative relationship between electrode’s 
fluorescence and antigen levels in the incubation solution.  In summary, the results in 
Figure 2-5 illustrate that the biologically-based assembly methods provide a simple and 
generic means to assemble antibodies (and antigens) at specific electrode addresses and 
that the protein G scaffold apparently had negligible interference with the assembly of 




Figure 2-5  Spatially-selective antibody assembly and antigen binding at electrode 
addresses of a patterned chip.  (a) Antibody was assembled by the following sequence: 
directed-assembly of chitosan by electrodeposition on the left electrodes; enzymatic-
assembly of the HG3T onto the electrodeposited chitosan; and self-assembly of FITC-
labeled anti-mouse antibody by binding to HG3T.  Fluorescence images and image 
analysis indicate spatially-selective and quantitative antibody assembly at the electrode 
addresses (R2=0.995).  (b) Antigen binding was studied by assembling goat anti-GFP 
antibody onto the left electrodes and incubating the chips with varying concentrations of 





Chitosan’s pH-responsive, network-forming properties also allow fibers to be 
spun or electrospun [111-113].  Chitosan fibers (Figure 2-6a) were prepared by injecting 
a chitosan solution into an ethanolic alkaline bath.  The fiber diameter was approximately 
500 um.  An initial study was performed to assemble two antibodies at separate locations 
on a single fiber.  This was achieved by simultaneously immersing each end of the fiber 
- +         +         +         +        + Tyrase - +
0.133      0.008      0.016     0.033     0.066     0.133 Antigen (μM) 0.091     0.091





































into separate antibody solutions; a goat anti-rabbit antibody labeled with Texas red (0.1 
uM) and a goat anti-mouse antibody labeled with FITC (0.1 uM).  The fluorescence 
image shows assembly of the labeled antibodies at separate “addresses” on the fiber 
while no fluorescence is observed in the middle of the fiber where no antibody was 
assembled.       
Assembly of antigen was similarly tested. Freshly extruded fibers were 
sequentially incubated with tyrosinase plus HG3T, anti-GFP antibody, and then dipped 
into solutions containing GFP.  The fluorescence photographs and associated image 
analyses indicate considerable GFP binding (Figure 2-6b).  In contrast, the control fiber 
on the left (tyrosinase was deleted during the HG3T assembly step) shows little 
fluorescence (both in the image and by image analysis).  Thus, antibody-presenting 
chitosan fibers can be readily generated for antigen capture.  
In studies analogous to the electrodeposited chitosan, we tested the extent to 
which the antibody and antigens could be assembled onto fibers.  While our results are 
promising, error due to the nonuniformity in fiber geometry (thickness or cross sectional 
area varies along fiber length), the antigen loading was difficult to quantify using image 
analysis.  To circumvent this difficulty, we dissolved individual fibers assembled with 
GFP using mild acid (0.1 M acetate buffer, pH 5.0) and measured the fluorescence in 
solution.  The relationship depicted in Figure 2-6c is indeed linear (R2=0.993), illustrating 
quantitative assembly of antibody and antigen onto chitosan fibers.  Indeed, the slope of 
Fig 2-6c also enables an estimate for the number density of GFP on the surface of fiber.  
That is, our results suggest that 5 pmole of the GFP antigen is bound per cm of the 
antibody-presenting chitosan fiber (diameter ≈ 0.5 mm).  If the average cross-sectional 
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area of GFP is estimated to be 8 nm2/molecule, then a “fractional” surface coverage of 
antigen on the fiber (area occupied by protein/fiber area) is on the order of 2.  This 
estimate suggests that antigen-antibody binding is not confined to the external surface of 
the chitosan fiber but, instead, suggests that some binding occurs within the fiber network.   
Analogous observations were made for antigen-antibody binding within agarose 
networks [114] and for nucleic acid hybridization within chitosan films [115]. 
The ability to generate antibody-presenting fibers also suggests the potential for 
creating woven fabrics with the ability to capture multiple antigens simultaneously.  We 
generated chitosan fibers with two different antibodies – one against GFP and a second 
against bovine serum albumin (BSA) – and we created a loose mesh of these two types of 
fibers.  This mesh was then immersed in a solution containing a mixture of both the GFP 
and BSA antigens (BSA was fluorescently labeled for imaging).  Fig 2-6d shows 
fluorescence images for this mesh and indicates that each antigen is assembled on its 
respective fiber.  These results indicate that woven fabrics can be prepared to capture 
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Figure 2-6  Antigen binding to antibody-presenting chitosan fibers.  (a) Optical 
micrographs provide a perspective of the fiber size (∼500 um diameter in this case).  The 
versatility of antibody assembly onto chitosan fibers is illustrated by the assembly of two 
different fluorescently-labeled antibodies at different ends of a fiber. Red indicates the 
binding of anti-rabbit (Texas red labeled); green indicates binding of anti-mouse (FITC 
labeled).  (b) The GFP antigen is observed to bind to the anti-GFP presenting fiber on the 
right while little GFP binding is observed for the control fiber at the left.  The anti-GFP 
presenting fibers were prepared by sequentially incubating the chitosan fibers in solutions 
containing: tyrosinase plus the HG3T protein; the anti-GFP antibody, and the GFP 
antigen.  Control fibers were prepared by deleting tyrosinase from the HG3T-assembly 
step. (c) Antigen binding as a function of fiber length (R2=0.993) suggests antigen-
antibody binding is not confined to the external fiber surface (see text).  Antigen (i.e., 
GFP) binding was analyzed after dissolving the fiber in mild acid.  (d) Simultaneous 
capture of two antigens by meshes woven from anti-GFP presenting fibers (vertical) and 
anti-BSA presenting fibers (horizontal).  The mesh was immersed in a solution 
containing both the GFP and labeled-BSA antigens. 
 
 
There may be applications that employ fibers for antigen capture (e.g., for 
environmental sampling), hence it would be desirable for the antibody assemblies to be 
stable in air for moderate amounts of time.  To test for stability, we prepared chitosan 
fibers and sequentially assembled HG3T, anti-GFP antibody, and the GFP antigen.   
Resulting fibers were then rinsed and dried at room temperature.  Fluorescence images of 
these air-dried fibers were obtained on the first and seventh days (Figure 2-7).  Image 
analysis of the fiber’s fluorescence intensity on the seventh day was estimated to be 95 % 
of that observed on the first day.  Since GFP’s fluorescence requires its native structure, 
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the above analysis suggests that this antibody-antigen assembly on the chitosan fiber is 
stable to room temperature storage in air. 
 
 
Figure 2-7  Stability of antigen-antibody assembly on chitosan fibers.  Fluorescence 
images of these air-dried fibers were obtained on the first and seventh days.  Image 
analysis of the fiber fluorescence intensity on the seventh day was estimated to be 95 % 












These studies demonstrate the use of three biologically-based fabrication methods 
for the hierarchical assembly of antibodies and antigens into macroscopic systems.  We 
created tryosine tagged protein G that offers a biologically-activatable interface between 
the antibodies and the pH-responsive chitosan that, in turn, can be cast, electrodeposited, 
and spun into various geometries.  Importantly, these biofabrication methods are simple 
and selective.  The results also suggest potential applications.  The chip studies show 
electrical signals can be enlisted to direct assembly, and suggest the potential for 
assembling antibodies at electrode addresses embedded within fully packaged 
microfluidic devices [116].  The fiber studies demonstrate high levels of antigen-antibody 
binding, and suggest the potential for antigen capture by smart fabrics.  Potentially, 
biologically-based fabrication methods will provide a broader range of options for the 




Chapter 3. Autonomous bacterial dirigibles – new 
synthetic biology platforms for “smart” sensor- 
actuator devices 
 Introduction 3.1.
The emerging practice of using bacteria as disease therapy vectors is gaining 
attention [28-30], even to the extent of a hypothesized alternative to anti-cancer agents 
such as standard chemo- and radiation- therapies [35-40].  To date, many genera of 
bacteria, including Salmonella, Escherichia, Clostridium, and Bifidobacterium have 
exhibited potential as cancer treating agents [32-34].  Indeed, Forbes (2010) [41] recently 
suggested characteristics of the ideal bacteria agent but did not describe innovative 
approaches that use the bacteria to make decisions that would enable autonomous 
delivery of disease-arresting therapeutics only to cancerous cells and not others.  
Bacteria naturally move and make decisions; programming these functions using 
synthetic switches has only recently appeared. Cheng et al. [29] demonstrated the in vitro 
use of engineered strain of E. coli bacteria to kill pathogenic P. aeruginosa by producing 
pyocin S5, a protein antibiotic in response to the presence of signaling molecules 
generated from P. aeruginosa.  The resulting pyocin S5 lead to the eradication of both P. 
aeruginosa and engineered E. coli. March et al. [28] showed the potential of using an 
engineered bacterial that produces cholera signaling molecule autoinducer 1(CAI-1) as a 
live vaccine.  They prevented Vibrio cholerae virulence in an infant mouse model.  These 
reports creatively exploit the natural signaling processes among bacteria and also 
reprogram their genetic circuits to generate user-specified positive outcomes.  What is 
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missing thus far are innovative measures to use high level functions of the bacterial cells 
that might enable them to accomplish even more.  
In this research, we demonstrate an innovative approach employing “smart” 
bacteria for the potential use in treatments of cancer and other diseases [41].  We  
generate a motile bacteria can provide both the means to find tumors, dock on associated 
receptors (“features”), integrate feature density, and then decide whether or not to take an 
action.  
This novel “smart” bacteria reinforces the notion of an expanding “Synthetic 
Biology” umbrella.  The general concept of synthetic biology encompasses the rewiring 
of a cell’s genetic circuitry for the synthesis of novel products using heterologous 
processes.  In this approach, typically all cells carry out the same function.  A less 
commonly examined but equally innovative strategy uses the reprogrammed cell as the 
product.  This report falls under the latter category.  Here we describe the synthesis and 
characterization of a modified E. coli K-12 whose behavior is governed by a synthetic 
genetic circuit which endows tunable targeting, sensing and switching capabilities.  The 
resultant cell is a bacterial “dirigible” – a cell that autonomously navigates and carries or 
deploys important “cargo”.  Using biomarkers, receptors, or other mammalian cell 
surface features, these dirigibles can target specific locales.  Sufficient accumulation at 
the target surface triggers an “on” switch in response to the biomarker density.  This 
serves as a phenotype “focusing” system and maintains the switch in an “off” state until 














Figure 3-1  Schematic plot of the bacteria “dirigible” model.  Bacteria targeting and 
switching are based on “feature” receptor densities of mammalian cells.  Bacteria cells 
will potentially dock onto mammalian cells with high feature density and subsequently 
turn on the switch if the feature density reaches the threshold. 
 
 
The dirigible’s switching capability relies upon bacterial quorum sensing (QS), a 
density-dependent cell-cell communication process among bacteria that is mediated by 
the transmission and propagation of chemical signals known as “autoinducers” [117, 118].  
Autoinducers are synthesized within the cell cytoplasm, secreted to the outside and 
accumulate in the cells’ immediate surroundings [119].  At a point associated with a 
“quorum” of cells, where the cell density and hence the concentration of the exported 
autoinducer reaches a threshold, the signaling molecules are transported back into the 
cells or are bound to cognate cell surface receptors, where they initiate coordinated 
changes in gene expression [50].  Several classes of signaling molecules and QS 
mechanisms have been identified [118, 120].  This work leverages the transduction of 
autoinducer-2 (AI-2) signaling which is the dominant form of bacterial cell-cell 
communication in Esherichia coli and Salmonella typhimirium, among other bacteria.  
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Specifically, we genetically rewired the E .coli W3110 QS circuitry by knocking 
out lsrF and LsrG (AI-2 degradation genes), and co-transformed QS responsive plasmids 
[54] for enhancing AI-2 sensing and actuating capabilities (Fig 3-2a) as compared to wild 
type.  In addition, we also utilized biological nanofactories (NF) (enzyme-based AI-2 
synthesis device comprised His tag, protein G, LuxS, Pfs, and Tyr tag) facilitate AI-2 
production [121].  Furthermore we integrated our modified bacterial “switch” with 
localization capabilities through two distinct, but complementary mechanisms.  First, we 
engineered bacteria to contain a generic scaffold for antibodies which provides specificity 
in binding to surfaces of interest (chips/mammalian cells).  Subsequent to dirigible 
targeting with antibody-nanofactory complexes, gene expression is turned on through a 
QS switch mechanism when sufficient AI-2 has been synthesized.  The second approach 
utilizes nanofactory AI-2 synthesis to drive chemotaxis which guides bacterial homing 
and also eventually turns on gene expression.  We demonstrate the feasibility and 
functionality of both switches using an in vitro cancer model as a target and discusses 





 Materials and Methods 3.2.
Cell strains and plasmid construction 
E. coli K-12 W3110 (lsrFG-, luxS-), generated using a one-step inactivation 
method [122], was the strain used throughout unless otherwise specified.  This strain 
responds to a significantly lower AI-2 concentration than wild type W3110 (Figure 3-2a).  
Squamous cell cancers of the head and neck, PCI-15B (provided by Dr. Jennifer Grandis, 
Univ. of Pittsburgh) that expresses EGFR at high levels, was chosen for the bacterial 
targeting; HEK293 (human embryonic kidney cell, ATCC number: CRL-1573) was used 
as the corresponding control for its low expression of EGFR. Both PCI-15B and HEK293 
cells were cultivated in Dulbecco’s Modified Eagle’s Media (DMEM) containing glucose 
(4.5 g/L), GlutMAX™ I (3.97 mM), and 10% fetal bovine serum (FBS, Sigma) at a 37oC 
incubator supplied with 5% CO2.   
To construct plasmid pET-DsRed_tac-ompAG1, which encodes DsRed and 
surface displayed protein G, we performed PCR to amplify the surface display fragment 
including outer membrane protein A and signal-peptide (lpp-ompA) using the template 
vector pTX101 (provided by Dr. George Georgiou, Univ of Texas, Austin) [123] and 
protein G fragment using the pET32-G3T vector[47].  Subsequently, a fusion of lpp-
ompA and a protein G gene fragment containing a Hind III site was generated again by 
PCR and then inserted into pET-DsRed with Hind III (NEB) ligation.  The resulting 
plasmid product was then co-transformed along with pCT6 [54] vector into W3110 





Bacteria response to in vitro AI-2 production  
For creating differential antigen surface densities, various concentrations of avidin 
(Rockland immunochemicals) were added to pre-treated biotin coated plates (Pierce).  
Anti-avidin (FITC) conjugated nanofactories with 1:2 weight ratio (1/200X dilution) 
were applied to guide the NF targeting toward the avidin surface.   
Bacteria, as descripted above, were resuspended in Dulbecco’s Phosphate Buffer 
(DPBS) (Sigma) containing 1mM S-adenosylhomocysteine (SAH; Sigma) and then 
incubated in the NF-treated plates.  Bacterial response to AI-2 production was monitored 
via their fluorescence response using a plate reader (SpectraMax M2; Molecular Devices).  
In-vitro AI-2 concentration was measured via a stoichiometric proxy, homocysteine with 
the Ellman’s assay.  
 
Controllable protein G expression on bacteria surface 
E. coli carrying plasmid pET-DsRed_tac-ompAG1 were induced with varied 
concentrations of IPTG (Sigma) and incubated at 37oC shaking at 250 rpm for 1.5 to2 
hours.  Cells were harvested and incubated with anti-mouse DL488 (Jackson 
immunoresearch).  Unbound antibodies were rinsed off and fluorescent images of 
bacteria taken to determine antibody conjugation efficiency or degree of protein G 
expression.  
 
In vitro bacteria targeting and switching/actuating  
E. coli cells were induced with 0.5 mM IPTG for 2 hours to express protein G 
followed by AF488 labeled mouse anti-EGFR (Santa Cruz Biotechnology) coupling.   
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Bacterial cells were then applied to a 96-well plate (Greiner Bio-One) cultivated with 
PCI-15B and HEK293 cells for EGFR targeting.  The wells were washed with DPBS to 
rinse off unbound bacteria and then treated with goat anti-mouse coupled nanofactories.  
After washing with DPBS, an S-adenosyl-homocysteine (SAH) solution was added to the 
wells and bacterial fluorescence response was assessed over 12 hours.  
 
Chemotaxis of in vitro synthesized AI-2  
In vitro AI-2, SAH, and homocysteine (Sigma), were diluted into equivalent 
concentrations (40uM) with DPBS and then added into the top compartment of transwells 
(3um porosity; BD Biosciences) in 6-well plates (Corning).  E coli cells resuspended in 
DPBS (OD600 ~0.15 to 0.2) were then applied gently into the bottom compartment 
surrounding and below the top compartment of the transwells.  The plates were then 
incubated at 30oC for 2 hours; bacterial cell density in the top compartment was assessed 
as a marker of cell motility.   
 
Chemotaxis and actuation of bacteria in response to in situ AI-2 produced by locally 
targeted nanofactories 
15B and HEK cells were seeded onto 1% gelatin treated glass slide (25mm round; 
Fisher Scientific) one day prior to experiments.  NF and anti-EGFR were co-incubated 
for 30 mins (2:1 molar ratio) and then diluted into 1% BSA-DPBS (1ug/100ul).  
Afterward, the cells were treated with anti-EGFR-NFs for one hour followed by rinsing 
with DPBS 3X and placed into 1mM SAH (DPBS) containing transwells (3um porosity; 













































hours followed by the addition of bacteria (OD600 0.15-0.2 in DPBS) into the bottom 
compartment for extra 6-hour incubation.  AI-2 production, bacterial migration, and 
actuation/response were examined by Ellman’s assay, OD600, and fluorescence 








Figure 3-2  Characterization of W3110 (lsrFG-, luxS-) and construction of pET-
DsRed_tac-ompAG1 vector. (a) AI-2 sensitivity of W3110 (lsrFG-, luxS-) vs. MDAI2 
(W3110 (luxS-)).  Both bacteria cells carrying pCT-6 + pET-DsRed_tac-ompAG1 
induced with various amounts of in vitro AI-2 concentrations for 8 hr. Subsequently cells 
were harvested and the positive DsRed population of bacteria in respond to AI-2 was 
measured by flow cytometry.  The results suggest W3110 (lsrFG-, luxS-) is more 
responsive than MDAI2 (W3110 (luxS-)).  (b) Incorporation of QS vector PCT-6 with 






 Results and discussions 3.3.
In order to create a “feature” surface for building the gradient of signaling 
molecules, two assembly strategies (synthetic and natural) are exploited for the assembly 
of gradient in binding molecules and cells.  In a synthetic system, various densities of 
binding molecules are generated through protein biofabrication.  In a natural system, 
different amounts of mammalian cells are seeded to form a gradient of surface bound 
receptors.  Both naturally and synthetically created surfaces are investigated subsequently 
for the bacteria switch. 
 
Antibody facilitated bacteria targeting and AI-2 generation  
We created a gradient of avidin densities on a series of chips/wells to biotin-
coated ELISA wells, depositing the target for FITC labeled rabbit anti-avidin conjugated 
HGLPT nanofactories (NF).  As depicted in Figure 3-3a, the NF has the capability to 
convert SAH into AI-2 through the Pfs and LuxS enzymes.  They also target antigens 
through protein G (IgG-binding motif, for antibody conjugation).  A gradient of avidin 
was created in multiwell plates resulting in different levels of NF binding.  This can be 
seen in Figure 3-2b where we both measured the level of NF binding and its 
corresponding AI-2 production as a function of avidin coated onto surfaces.  A strong 
positive correlation between both curves was observed.  That is, both curves were similar.  
Also, both curves achieved saturating signals at avidin levels above 50 ng.  We 
inoculated these surfaces with SAH and bacteria W3110 (lsrFG-, luxS-) which carries 
vectors pCT6 + pET-DsRed_tac-ompA-proteinG in a 37oC incubator.  DsRed responses 
of bacteria samples were characterized by measuring the DsRed fluorescence with a plate 
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reader over time.  As indicated in Figure 3-3c, the trends of all curves correlate to the NF 
binding (Figure 3-3b), that is, increased fluorescence with avidin.  Time course curves 
indicate the overall DsRed intensities increased over time (8, 16, 19, and 26 hr), 
suggesting AI-2 concentration increased along the time frame in the experiment.  While 
low DsRed was observed for the control sample without SAH at 26hr, suggesting no AI-2 
was produced.  The results depicted in Figure 3-2b and 3-3c, we demonstrated the ability 
to control the binding of NF to a specific surface through antigen-antibody interaction 
and calibrate subsequent AI-2 productivity.  We also demonstrated the bacteria we 
engineered were capable of actuating DsRed gene expression in response to various 
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Figure 3-3  NF targeting and bacteria response on varied densities of avidin coated 
chips/wells. (a) Conceptual plot for NF targeting on various densities of avidin chips. 
NFs are fusion proteins comprised of Pfs, LuxS (for In vitro AI-2 synthesis) and protein 
G ( IgG-binding motif, for antibody conjugation).  Anti-avidin (FITC) coupled NFs target 
to avidin chips and catalyze SAH to AI-2. Note the chips here represent the biotin-avidin 
treated plate wells. (b) NF targeting and subsequent in vitro AI-2 syntheses on avidin 
plate wells. NF targeting was determined by a fluorescence plate reader (FITC) and AI-2 
concentrations were measured by Ellman’s assay. (c) W3110 (lsrFG-, luxS-) response to 
in vitro AI-2 synthesized by NF targeting on avidin plate wells. Suspension of bacteria 




Next, we developed a strategy to elucidate spatially-resolved “docking” of 
bacteria.  We utilized the bacteria outer membrane protein A (ompA) as a transmembrane 
domain to display Streptococcal protein G on the outer cell surface.  This allows ex vivo 
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assembly of potentially any antibody for targeting and “docking” bacteria to any 
specified surface.  An ompA and protein G DNA fusion was PCR-amplified and ligated 
into pET-DsRed vector under the control of a tac promoter.  In parallel, we created an 
AI-2 based expression control “cassette” and inserted DsRed as a marker.  The resultant 
pET-DsRed_tac-ompAG1 vector (Figure 3-2b) was transformed into E. coli W3110 
(lsrFG-, luxS-).  The subsequent strain was capable of expressing protein G in response to 
IPTG and DsRed in the presence of AI-2.  Figure 3-4 depicts the expression profile 
induced by varied concentrations of IPTG.  Bacteria W3110 (lsrFG-, luxS-) which carries 
vectors pCT6 + pET-DsRed_tac-ompA-proteinG was induced by varied concentrations 
of IPTG (0, 0.05, 0.1, and 0.5mM).  After 1.5~2hr induction at 37oC 250 rpm shaking, 
the relative expression levels of protein G of bacteria were quantified.  Through 
visualization afforded by DL488 labeled anti-mouse IgG staining, protein G expression 
level was titrated through both fluorescence images and flow cytometry (Figure 3-4a and 
3-4b respectively).  The DL488 fluorescence intensities increased with IPTG suggests the 
increase of protein G expression level in both Figure 3-4a and 3-4b, while minimized 
DsRed were observed in Figure 3-4a.  This tunable expression of surface displayed 






























Figure 3-4  Tunable protein G expression from W3110 (lsrFG-, luxS-) carrying vectors 
pCT6 + pET-DsRed_tac-ompAG1. Protein G expression profile was determined by 
inducing with varied concentrations of IPTG. After 1.5~2hr induction, the relative 
expression levels of protein G of bacteria were quantified.  Through visualization 
afforded by DL488 labeled anti-mouse IgG staining, protein G expression level was 
titrated through both fluorescence images (a) and flow cytometry (b). 
 
 
We hypothesized that the engineered bacteria could both target and actuate by 
using a “smart” switching functionality.  The cells were equipped with FITC labeled anti-
avidin by protein G conjugation.  These complexes were then applied to the avidin pre-
treated biotin plate (same avidin setup as Fig 3-3a).  Next, 40uM in vitro AI-2 was added 
to the targeted cells and DsRed responses were measured after 12 hours.  In Figure 3-5a 
the assembled cell number (indicated by green fluorescence) increased with avidin.  As 
depicted here, images from the 0 hour time point suggest the amount of E. coli targeting 
is positively proportional to avidin density on the plate (FITC channel) except the 250ng 
well, where binding may have already plateaued.  Moreover, the cells only expressed low 
background level of DsRed initially.  After 12 hours, however, cells incubated with AI-2 
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were significantly more fluorescent compared to those without AI-2.  In addition to the 
qualitatively observation, we further performed the particle analysis using ImageJ 
software for further quantitation.  As indicated in Fig 3-5b again, a linear relationship 
between bacteria docking and avidin density were observed for all curves, FITC (0hr), 
DsRed (0hr), and DsRed (12hr; with AI-2 addition) at avidin density less than 50ng.  The 
FITC (0hr) curve matched comparably to the DsRed (+AI-2; 12 hr) which suggests most 
of the docked bacteria basically were switched on after AI-2 addition.  Almost no DsRed 
cells were observed in the treatment without AI-2 after 12 hr.  And interestingly, the 
number of DsRed positive cells at 0 hr time point was slightly higher than cells that 
without AI-2 addition at 12 hr (39 vs 6) and the reason is not known.  However, we 
speculated that DsRed was metabolized or degraded after 12 hr without any new DsRed 
synthesized. Overall, we demonstrate the cells can target and then subsequently actuate in 











































Figure 3-5  AI-2 response of docked W3110 (lsrFG-, luxS-) (pCT6 + pET-DsRed_tac-
ompAG1) on avidin coated wells. (a) W3110 cells with surface displayed protein G were 
treated with FITC labeled anti-avidin and then applied to various densities of avidin wells. 
Unbond bacteria were washed followed by 40uM AI-2 addition. Fluorescence images at 
0 and 12 hours were taken by fluorescence microscopy. (b) Image analysis of Figure 3-5a 
using ImageJ to determine the bacteria number targeted on the avidin surfaces. The 
relationship between cell number and avidin density was plot. 
 
 
To test the integration of all these elements, we selected two mammalian cell lines, 
PCI-15B and HEK293, as our surfaces of interests for their contrasting high and low 
expression of EGFR, respectively.  As indicated in Figure 3-6a, we first seeded both PCI-
15B and HEK293 in 96-well plates at varied density.  Next, we prepared W3110 cells 
with mouse anti-EGFR coupled to their surfaces followed by applying the bacteria cells 
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to the PCI-15B and HEK293 cells cultivated in 96-well plates for targeting.  
Subsequently, goat anti-mouse conjugated nanofactory complexes were directly bound to 
bacteria cell surfaces to assist in tuning the switch.  Finally, we added SAH into the wells 
and incubated at 37oC in 5% CO2 for 12 hours to test whether the bacteria docked onto 
eukaryotic cells could respond to AI-2.  As shown in Figure 3-6b, the fluorescent and 
bright field images indicate that the anti-EGFR-bacteria bind specifically to the cell 
surfaces of interest.  The staining on the HEK293 monolayer is significantly less than that 
on the PCI-15B monolayer. After a 12-hour incubation with SAH (Figure 3-6c), the 
bacterial cells turn on DsRed expression on PCI-15B only at the two highest mammalian 
seeding densities (20,000 and 10,000 cells/well).  DsRed expression indicates the QS 
switch was “on”.  Wells with low PCI-15B densities or without NF treatment had 
minimal DsRed expression, similar to the HEK293 control cell surface.  We further 
processed the image data from anti-EGFR-bacteria binding (Figure 3-6b) and DsRed 
response (Figure 3-6c) experiments using ImageJ and resulted in Figure 3-6d and Figure 
3-6e respectively.  As the NF complexes were applied in excess for these experiments, 
the amount of NF attached to the mammalian target surface was assumed to be directly 
proportional to the bound bacteria population.  As seen in Figure 3-6d, a linear 
relationship between fluorescence of AF488-anti-EGFR (bacteria number) and 
mammalian cell density was observed for cell seeding densities below 10,000 after which 
point the signal saturates.  This bacteria number- to-mammalian density linear 
relationship was not, however, reflected in the switching response, which as shown in 
Figure 3-6e, was kept tightly off until the cell seeding density reached 10,000, at which 
point DsRed expression was turned on.  This indicates the QS switching here has a 
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threshold limit for actuation directly related to EGFR “feature” densities.  We envision 
this engineered E. coli could potentially be used in conjugation with NF as a relatively 
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Figure 3-6  W3110 (lsrFG-, luxS-) (pCT6 + pET-DsRed_tac-ompAG1) targeting and 
actuating on mammalian cell surface.  (a) Scheme of bacteria targeting to receptors of 
mammalian surface and subsequent NF conjugation to targeted bacteria for locally AI-2 
synthesis and delivery to trigger bacteria switches.  The procedures are as follow: anti-
receptor Ab coupled bacteria (through prtein G) target to EGFR on cell surfaces, 
secondary Ab-NFs target to bound bacteria, and NFs convert SAH into AI-2 for bacteria 
actuation.  (b)As indicated in (a) various densities of PCI-15B or HEK cells were seeded 
to wells followed by mouse anti-EGFR (AF 488 Labeled) bacteria, anti-mouse-NF 
targeting and subsequent SAH addition.  (c) Bacteria responses/ DsRed expression were 
measured after 12 hour incubation.  (d) Further analyses of images from (b) to obtain the 
correlation curve between mammalian cell seeding densities and amount of bacteria/NF 
binding. ImageJ was utilized to determine the AF488 fluorescent intensities.  (e) 
Relationship between bacteria responses and cell densities were investigated to determine 
the threshold of the switch. 
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AI-2 guided bacteria homing and actuation 
A second strategy to assess bacteria localization is to decorate the target feature 
itself with NF, and synthesize AI-2 directly at the target to attract bacteria by exploiting 
native bacteria AI-2 chemotaxis.  First, to test whether AI-2 is a chemoattractant for E. 
coli K-12 W3110, experiments were conducted with a transwell setup to allow AI-2 
diffusion across the membrane generating a concentration gradient. 40uM in vitro AI-2 
was added to the top, luminal transwell compartment and W3110 to the bottom, 
basolateral compartments in 6-well plates.  The transwell containing plates were 
incubated for 2 hours at 37oC with no shaking.  AI-2 diffusion was simulated using a 
finite element modeling method with a diffusion coefficient of 3x10-8 to confirm gradient 
formation.  Simulation results from Figure 3-7a showed the pattern of gradient formation 
was similar between the duration of 1hr and 2hr time point, suggesting that the limiting 
dimensions between transwell compartments prevent gradient dissipation during the 
relevant experimental time frame.  After 2 hr incubation, optical densities (OD600) of both 
top and bottom compartments were measured to determine the number of migrated 
bacteria.  Cell counting was performed by taking bright field images of the top 
compartment samples.  As shown in Figure 3-7b, the cell density in AI-2 sample was 
significantly higher than SAH sample, indicating AI-2 was effectively attracting more 
bacteria. Similar results (Figure 3-7c) were seen for OD600 measurements, in which the in 
vitro AI-2 induced chemotaxis.  The OD in top AI-2 well was initially 2.8-fold of SAH 
and significantly increased to 34-fold after 2 hr incubation. The OD of bottom SAH well 
did not change after a 2-hour incubation, while the AI-2 bottom well dropped 
significantly by 30%. In another experiment (Figure 3-8), we tested several other buffers, 
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including homocysteine (a by-product of AI-2 synthesis), Tris-HCl, and DPBS and 




Figure 3-7  AI-2 chemotaxis on E. coli W3110 (lsrFG-, luxS-) (pCT6 + pET-DsRed_tac-
ompAG1).  (a) Simulation of in vitro AI-2 diffusion profile across the transwell 
membrane (from top to bottom) using COMSOL software.  Chemotaxis experiment was 
performed as followed. 1.5ml of in vitro AI-2 and SAH (40uM) was added into top parts 
of the 3um -6 well inserts. Bacteria cells (OD~ 1-1.5) rinsed with DPBS three times were 
then resuspended into DPBS (OD ~0.2-0.3) and applied into bottom wells. The inserts 
were incubated static at 37oC for 2 hours. Bright filed images of cell migrated to top well 
were taken (b). And a systematic OD characterization was conducted for the bacteria 






















Figure 3-8  Effect of AI-2 and relevant chemicals on W3110 (lsrFG-, luxS-) (pCT6 + 
pET-DsRed_tac-ompAG1) chemotaxis. Equivalent molar concentration (40uM) of AI-2, 
SAH (precursor of AI-2), Homocysteine (side product of in vitro AI-2 synthesis), and 
buffer (DPBS, Tris-HCl) were tested for chemoattactants. 1.5ml of Samples was added 
into top parts of the 3um -6 well inserts. Bacteria cells (OD~ 1-1.5) rinsed with DPBS 
three times were then resuspended into DPBS (OD ~0.2-0.3) and applied into bottom 
wells. The plates were incubated static at 37oC for 1.5 hours. OD of the bacteria inside 
the insert was measured afterward. 
 
 
We demonstrated that NF production of AI-2 at the mammalian cell surface is 
capable of attracting bacterial cells in response to the AI-2 gradient and subsequently 
triggering “dirigible” switching behavior.  A schematic of this experimental setup is 
depicted in Figure 3-9a.We first seeded the mammalian cells (15B and HEK) on gelatin 
coated glass coverslips, introduced anti-EGFR- NF complexes and applied SAH into the 
top transwell compartment.  We placed the gelatin coverslip upside-down to face 
mammalian cells toward bacteria.  The W3110 cells were added into the lower wells 
afterward.  After 9-hr incubation of the transwell setup, we checked whether the bacteria 
will be able to migrate toward up and then target to mammalian surfaces by measuring 
OD, in vitro AI-2 concentration , as well as taking fluorescence images.  After selectively 
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targeting NF to the surface of interest (green images of Figure 3-9b), AI-2 was locally 
synthesized adjacent to the mammalian cell surface (15B and HEK) creating a 
concentration gradient, which attracted bacteria chemotactically as an analogous “homing” 
signal.  Compared to 15B cells, HEK cells showed less green EGFR binding (similar to 
Fig 3-6b).  The resulting differential DsRed bacteria observed on the red channel images 
suggest different amounts of bacteria migrated up and across the transwell barriers 
(Figure 3-9b).  For 15B+SAH well, high density of DsRed bacteria was observed as 
compared to 15B+PBS, almost no DsRed bacteria. Also, few DsRed-expressing bacteria 
were seen on HEK+SAH.  The results correspond to the AI-2 concentration profile 
(Figure 3-9c) and OD measurement of the bacteria cell density in top well (Figure 3-9d).  
As Indicated, the highest bacteria density was observed in the wells treated with 
15B+SAH and lowest in 15B+PBS treated wells.  Importantly, a significantly higher 
density of dirigibles also displayed switch responses in the 15B+SAH wells compared to 
the HEK+SAH wells, while a minimal switching density was observed in 15B+PBS 
control wells. Interestingly, the in-vitro AI-2 quantified in 15B+SAH sample was 5uM 
which corresponded to the previously determined threshold for QS switch [121].  Note 
here that AI-2 played a dual role both guiding bacteria chemotaxis and also triggering the 
switching response (DsRed reporter expression, Figure 3-9b).  In summary, the docking 
of anti-EGFR-NF onto mammalian cell surfaces was specifically controlled by EGFR 
surface density which strongly correlated to subsequent AI-2 synthesis, bacteria 



















































Figure 3-9  Bacteria chemoattraction and actuation through AI-2 synthesis of NF. (a) 
Bacteria switch: schematic represents the targeting of NF to surface of interests, e.g. 
cancer cell surfaces, AI-2 production locally on the surfaces, AI-2 gradient through 
random diffusion, and then subsequent bacteria attracting and actuating. Mammalian cell 
surface is facing upside down in order for bacteria migrating toward them in the transwell 
configuration. (b) Results of the bacteria switch: anti-EGFR-NFs binding to EGFR on 
both 15B and HEK cells were shown on the AF488 (green fluorescence) images and 
bacteria attracting, docking, and DsRed expression were presented on the red 
fluorescence images. Corresponding AI-2 production was determined by Ellman’s assay 






We demonstrated the use of engineered bacteria with a rewired quorum sensing 
circuit as a potential dirigible switch, the features of which comprise targeting, sensing, 
and actuating capabilities.  We have created and tested two complementary targeting or 
localization schemes to demonstrate dirigible switching on mammalian cell targets in an 
in vitro cancer model.  First, dirigibles and nanofactories were independently and 
specifically bind to the mammalian cell surface.  Bound bacteria could sense and respond 
to locally synthesized AI-2 by the nanofactories.  Additionally, we also carried out a 
second dirigible strategy leveraging the AI-2 produced by the docked nanofactories as a 
homing signal for attracting dirigibles (chemotaxis) and actuating the dirigible phenotype 
switch.  For both targeting and localization schemes, the dirigible response was 
controlled by AI-2 concentration, which primarily depended on the cell receptor, or 
“feature” density.  The higher feature densities on 15B cells allowed more nanofactories 
to dock, thereby increasing the effective local AI-2 concentration. Correspondingly, the 
overall densities of triggered bacteria were significantly more on 15B surfaces than 
comparative HEK293.  The mechanism provides a reasonable and discernible means to 
ensure site specific actuation, providing a more focused and effective phenotype.  We 
envision this novel bacterial dirigible scheme, that integrates both targeting and switching, 




Chapter 4. Tuning cell cycle of insect cells for enhanced 
protein production 
 Introduction 4.1.
There exists great promise for whole promise genome engineering for the 
production of both commodity products and high value therapeutics, that enable 
glycoprotein expression and purification from E. coli[124] , particularly when coupled 
with the considerable power of bacterial genome engineering [125], hold promise to 
transform the commercial protein synthesis landscape. 
The integration of innovative molecular tools to metabolically engineer cells for 
expression of expression of recombinant proteins has and will continue to afford 
significant gains, particularly if both localized genetic circuits and global regulatory 
structures can serve to guide fluxes through specific bottlenecks in the context of a 
favorable landscape, respectively.  Both synthetic and altered native controllers are 
developed to guide protein synthesis, many transcending the host cell system.  In 
eukaryotic (mammalian, insect) cell systems, which provide superior glycosylation 
capabilities, interfering RNA (RNAi) is used to target local bottlenecks [75] as well as 
global processes [126]. 
Eukaryotic cell cultures remain the main sources for the production of 
pharmaceutical proteins despite their relatively low growth rate and protein yield as 
compared to prokaryotic expression systems [25-27].  This is mainly due to the enhanced 
quality of the product protein [47, 127].  Low mammalian cell growth rates and yields are 
due to a complicated network of regulatory mechanisms that monitor and check their 
internal physiological conditions, metabolic activities, as well as the absence of external 
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signals as a precondition to cell proliferation [128-130].  These cells progress through 
chromosome duplication and cell division in a process called the “cell cycle”.  The cell 
cycle consists of many checkpoints during which certain conditions must be met before 
passing to the next stages.  This strategy which ensures cell integrity and survivability 
can, however, sometimes compromise growth rate and protein synthesis.  Since cell cycle 
and proliferation status are closely related to protein synthesis activity [63, 131-133] the 
cell cycle is a potential metabolic engineering target.  Metabolic engineering approaches 
to arrest the cell cycle at specific states have been demonstrated as advantageous for 
recombinant protein production in eukaryotic cells [127, 134, 135].  
The eukaryotic cell cycle can be divided into four distinct phases:  gap-1(G1), 
DNA synthesis (S), gap-2 (G2), and mitosis (M) [127, 136].  Cells arrested at G1 (protein 
synthesis) phase have been shown to exhibit the highest ribosome biogenesis and protein 
translation activity of any cell cycle phase, resulting in higher recombinant protein yields 
[64, 137].  In G1 phase, cell resources are utilized more efficiently for synthesizing 
proteins of interests without diverting energy to produce cell components for proliferation 
[134, 135, 138].  For example, Bi et al. (2004) [139] showed that over-expression of the 
cyclin-dependent kinase inhibitor p21 causes G1-phase cell cycle arrest in Chinese 
hamster ovary (CHO) cells.  These G1-arrested cells showed an increase of mitochondrial 
mass and activity as well as ribosomal protein S6 translation levels, culminating in a 4-
fold increase of recombinant protein productivity.  Although cell cycle control has been 
demonstrated in mammalian cell lines for recombinant protein production, few studies 
have examined the feasibility in insect cell expression system. March and Bentley (2007) 
[75] successfully arrested cells in G1 phase and increased the target GFP production by 
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4-fold in Drosophila S2 cell line using  dsRNA technology (RNA interference) to 
knockdown the cyclin E (positive regulator for G1-to-S phase) expression.  This study is, 
as far as the authors are aware, the only reported use of RNAi approaches to control the 
cell cycle and recombinant protein production in eukaryotic cells.  We therefore found it 
worthy to pursue such an approach in a more industrially relevant insect cell line, such as 
the High Five cell line derived from the cabbage looper (Trichoplusia ni). 
In this research, we use a dsRNA knock down strategy against Trichoplusia ni (T. 
ni) cyclin E (CycE) to manipulate the cell cycle of T. ni cell line. In normal cell 
proliferation, Cyclin E is regulated so that a natural increase and subsequent decrease 
guides the G1 to S transition [133].  Hence, our hypothesis is that altered CycE level can 
lead to alter cell cycle decision-making process and that lead to altered phenotype. 
Specifically the sustained up-regulating of CycE leads to over-proliferation.  Also down-
regulating of CycE would essentially stall the transition S phase from G1.  Thus we 
investigate the effect of cell cycle regulation on both cell physiology and protein 
production in T. ni (High Five) cell cultures using the baculovirus expression system.  
Specifically, we identified the complete T. ni CycE genetic sequence, then up-regulated 
CycE expression by transfecting High Five cultures with an expression vector carrying 
CycE.  Next, the CycE gene expression was down-regulated via dsRNA against CycE.  
For both experiments, CycE transcription level, cell growth, as well as cell cycle 
distribution were examined.  Finally, the dosage-dependent effect of dsCycE on 





 Materials and Methods 4.2.
Cell culture 
T. ni BTI-TN-5B1-4 (High Five™, Invitrogen) cells were cultivated in EX-
CELL™-405 media (SAFC Biosciences) at 27 °C in T75 flasks (Corning) for adhesion 
culture.  Cells were also adapted to suspension culture by cultivated in 125 ml shaker 
flasks (Corning) with ~120rpm at room temperature.  Cell passage was conducted every 
two to three days, or whenever cell density reached confluency or (2.5~3 million 
cells/ml), and then split into 0.6 to 0.8 million cells/ml.   
 
Baculovirus amplification and Infection 
A recombinant A. californica multiple nucleopolyhedrovirus (AcMNPV) that 
expresses GFPuv under the control of the polyhedron promoter was created previously 
[140].  The baculovirus was amplified in S. frugiperda (Sf-9) cells (Invitrogen) according 
to the standard protocols with MOI (=0.1) and harvested the supernatant of cell media 
after centrifugation.  Baculovirus titer was determined by the endpoint dilution with 
GFPuv fluorescence measurement using a fluorescence microscopy (BX60; Olympus), a 
plate reader (SpectraMax M2; Molecular Devices), or flow cytometry (FACSCanto II; 
BD Biosciences).  
 
Identification of CycE sequence 
In order to determine the initial putative primers sequences for RT-PCR, CycE 
sequences among inter-interphylum species were collected from NCBI Genbank and 
multiple sequences alignment was performed by Clustal X software (EBI) to obtain the 
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consensus regions and subsequently the degenerate primers for PCR were designed as 5’-
GARGARATYTAYCCNCCHAAR-3’ (R: A/G; Y: C/T; N: A/T/C/G; H: A/T/C).  Next, 
RACE RT-PCR was performed with the degenerate primers.  Briefly, total RNA of High 
Five cells was extracted using RNAquous (Ambion) followed by reverse-transcription via 
SMART-RACE cDNA amplification kit (Clontech).  The resultant PCR products were 
ligated into TOPO TA vector (Invitrogen) and subsequent DNA sequencing was carried 
out by IBBR sequencing facility (DNA sequencer 3730; Applied Biosystems) to obtain 
the T. ni CycE cDNA sequence. 
 
pIB-TnCycE vector construction 
CycE gene was first PCR amplified using accuprime Hi Fi polymerase (Invitrogen) 
and TOPO-ligated into pIB/V5-His vector (Invitrogen) to generate pIB-TnCycE vector.  
The ligation products were transformed into E. coli TOP 10 competent cells (Invitrogen) 
and then plated to LB/agar (Fisher Scientific) with Kan 50 ug/ml at 37oC for overnight 
growing.  Single colony of cells was picked and inoculated into LB broth (Fisher 
Scientific) with Kan 50 ug/ml at 37oC 250 rpm for overnight.  Plasmids were purified 
with miniprep kit (Qiagen) and the concentrations were quantified by NanoDrop (Thermo 
Scientific).  DNA sequencing of CycE insertion was carried out to confirm the success of 
the cloning works. 
 
In vitro double stranded RNA (dsRNA) synthesis 
In vitro dsCycE was synthesized using the Megascript Kit (Ambion).  T7 
promoter sequence was incorporated to both 3’ and 5’ end of partial CycE fragments by 
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PCR with primers which had extra T7 promoter overhang.  In vitro transcription of 
dsCycE (800 bp) was then generated according to the manufacture instruction.  Briefly, 
the single stranded CycE was synthesized and then extracted using phenol/chloroform 
(Sigma) followed by resuspending in nuclease free water.  Subsequently, ssCycE was re-
annealed into dsCycE by denaturing at 65oC for 10 min and then slowly cooling to room 
temperature.   Double stranded chloramphenicol acetyl transferase (dsCAT) was 




RNAi or plasmid vector delivery was carried out by utilizing a transfection 
reagent Fugene HD (Roche) followed by manufacturing procedures.  Various amounts of 
RNAi were first diluted into RNase free water (Ambion) followed by mixing with 10 ul 
of Fugene into final 100 ul mixtures. The RNAi mixtures were incubated at room 
temperature for 10 minutes and then gently added to cell samples.  Cells samples were 
harvested afterward for further analyses. 
 
Cell cycle analyses 
For analyzing cell cycle distribution of RNAi or plasmid transfected cells, they 
were harvested and suspended into 300ul of cold DPBS (Sigma) followed by adding 
700ul of 100% cold EtOH dropwise with gently vortexing and incubating in ice for 15 
minutes.  Subsequently, cell samples were pelleted and resuspended into propidium 
iodide (PI; Sigma) staining solution (50 ug/ml PI; 0.1 mg/ml RNase A (Sigma); 0.05% 
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Tritin X-100 in DPBS) for 40 min at 37°C.  The stained samples were pelleted by 
centrifugation and resuspened back into DPBS for analysis using flow cytometer with red 
fluorescence channel filter.  
 
Cell growth  
Viable cell density of High Five cells was measured by using a hemocytometer 
with trypan blue staining solution to exclude the dead cells.   
 
Semi-quantitative RT-PCR   
To determine relative transcription levels, High Five RNA was extracted the 
concentration was quantified by NanoDrop (Thermo Scientific) and first strand templates 
of each sample were synthesized from 500 ng of RNA using Superscript RT III 
(Invitrogen) kit with oligo-dT primers.  The first strand cDNA was PCR amplified using 
CycE primers.  Actin primers for PCR amplification were chosen for the internal controls 
from the RT treatments.  The resultant PCR products were checked by 1% agarose gels 
(Fisher Scientific) and images were taken with a gel imaging camera (AlphaImager HP; 
Alpha Innotech). 
 
Recombinant his-tagged CycE protein purification and western blotting 
To express the histidine-tagged CycE protein, A T25 flask of High Five cells were 
transfected with pIB-TnCycE vector by Fugene HD (4ug/ml) and cultivated for 4 days 
before harvested.  The cell samples were pelleted and lysated by CytobusterTM solution 
(EMD chemicals) in ice for 40 minutes.  Subsequently, the cell lysates were purified 
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using TALON metal affinity resin (Clontech) followed by the instruction.  The resultant 
protein sample was dialyzed overnight in DPBS using dialysis tubing (Spectrum 
Laboratories).  Samples were then run on a 12.5% SDS-PAGE gel and then transferred to 
nitrocellulose membranes by a BioRad Trans-Blot semi-dry transfer cell.  After 5% milk 
blocking and rinising steps, western blotting was performed to detect the purified CycE 
using rabbit polyclonal anti-human cyclin E antibody (Rockland immunochemicals) with 
1:500 dilution ratio.  Secondary antibody incubation was carried out by using the alkaline 
phosphatase labeled goat anti-rabbit (Sigma) with 1:500 dilution.  Color developing step 










 Results and Discussion 4.3.
Identification of T. ni CycE and protein characterization 
We used RACE RT-PCR to identify CycE sequences.  Results indicated that the 
complete cDNA sequence was 1,518 bp, which would encode a 506 aa protein.  We 
performed both nucleotide and protein BLAST analyses, which revealed significant 
sequence homology with cyclin E families of different eukaryotics.  Figure 4-1a shows 
the CycE protein sequence alignment between the putative T. ni and related species, 
Bombyx mori (silkworm), Drosophila melanogaster (fruit fly), and Aedes aegypti 
(mosquito).  Sequence homology was significant but not identical, while B. mori had 
76.75% identity at the amino acid level; D. melanogaster and Aedes aegypti were less 
(45.14% and 41.74% respectively).  
In addition to sequence validation, we used western blot analyses against human 
cyclin E to further characterize the T. ni CycE at a molecular level.  That is, the putative 
full length CycE was cloned into the insect cell expression vector (pIB/V5-His) yielding 
plasmid pIB-TnCycE, which was transfected into High-five cells to express a putative 
histidine-tagged CycE.  This protein was purified and probed via rabbit polyclonal anti-
human cyclin E.  Subsequent band development with Alkaline Phosphatase (AP) labeled 
goat anti-rabbit IgG and BCIP/NBT signal detection suggested the expressed protein was 
indeed a CycE (Figure 4-1b).  Specifically, controls protein GFPuv yielded no signal 
(Lane 4).  Moreover, the band from the CycE sample was observed between MW 64.2 
and 48.8KDa, which match the theoretical MW (61.3 KDa) of the his-tagged, putative 
CycE.  Finally, the band intensity indicated on the western blot increased with a doubling 
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of loaded sample.  Overall, the newly identified gene and protein product appeared by the 


































Figure 4-1  Characterization of T. ni CycE protein. (a) Protein sequence alignment 
results between T. ni and its’ relatively close species, Bombyx mori (silkworm; NCBI 
Trichoplusia_ni               1 -------MAQTGSVCESSEKRLTLKRKRN-----STDDELENMPPLK----------ISP 
Bombyx_mori                   1 -------MAESGSPSEASEKRMTLKRKRS-----SSDDELENQPPQK----------IAS 
Drosophila_melanogaster       1 MKLEQKRKFIEMDPELGFEPPSAKRQQRLPALYGSEQGNLSSVASSVYTSPVVSVDGQST 
Aedes_aegypti                 1 MDLYSSEDASRSSTSEITEPRSRNSRKRK---YTSDDADIENQRPSKRHGGDRRLSPIAA 
 
Trichoplusia_ni             39 VLEEELNDQPAHNVVVESSSCSS---DDEGSQYGAVDQPRS--VYTDLDYNPDSFLSPPS 
Bombyx_mori                 39 TLDEQLCDQPALHVVVESSSCSS---DDEGSQYGNSDQPRS--VYTDIDYNPDSFLSPPS 
Drosophila_melanogaster     61 QELLSIRSSPAEDLSEAPHSPLPDSPDSPPSPDRGSKQTPVVVRYAAEQVVTSTVVTQKT 
Aedes_aegypti               58 SSAPSVP-IPSVASSAASSNSVP-SINIGSSEYTSDTQSSSDCYSTTADFELYPLVSPPS 
 
Trichoplusia_ni             94 ISD----------------------------------LPNCVLSPLENVARGESTP---- 
Bombyx_mori                 94 VSD----------------------------------LPNSVLSPLENVARGESTP---- 
Drosophila_melanogaster   121 EDDDLLDDSCEDYSYDEDDEDDVEEEDDDVEIYSSTISPASSGCSQQQAVNGERTPGLPK 
Aedes_aegypti             116 VNSIILSPSCEVSHGSWHTKGDTTPHAN---------RKSSSHSNQQQQRHNENSN---N 
 
Trichoplusia_ni           116 ---HSNKRPSTSKIPCPTLPK-------RKCPLPRLSWADPGDVWNSMCDCDARSSNRKN 
Bombyx_mori               116 ---HSNKRANASKPPCPTPPK-------RKCPLPGLSWADPADVWNSMCECDARSSKKKN 
Drosophila_melanogaster   181 HQEQIHHPVSDLMINMRTPMSPAVENGLRQCPLPALAWANAADVWRLMCHRDEQDSRLRS 
Aedes_aegypti             164 SSSKSSSNVPPALSCCVTPSS-----DLRSCPLPRFAWADSNQVWKLMCRKDEKASLERE 
 
Trichoplusia_ni           166 PNMFDNHPNLQPRMRAILLDWLNEVCEVYKLHRETFHLTVDYVDRYLSNTEDVQKGRLQL 
Bombyx_mori               166 PNMFDNHPNLQPRMRAILLDWLNEIGTKKTRQMRVRKLTAEGFR--------------SQ 
Drosophila_melanogaster   241 ISMLEQHPGLQPRMRAILLDWLIEVCEVYKLHRETFYLAVDYLDRYLHVAHKVQKTHLQL 
Aedes_aegypti             219 PNMFDQHPGLQPRMRAILLDWLIEVCEVYKLHRETYYLAVDYIDRFLSRKKEQKKTHLQL 
 
Trichoplusia_ni           226 IGITCLFIAAKVEEVYPPKIGEFAYVTDGACTTDEILLEELLILKILSWSITPITINSWL 
Bombyx_mori               212 VCITCLFIAAKVEEVYPPKIAEFAYVTDGACTTEEILLEELLILKILSWSITPITINSWL 
Drosophila_melanogaster   301 IGITCLFVAAKVEEIYPPKIGEFAYVTDGACTERDILNHEKILLQALDWDISPITITGWL 
Aedes_aegypti             279 LGITALFVAAKVEEIYPPKIGEFAYVTDGACSEDDILREELLLLSELQWSINPVTVMGWL 
 
Trichoplusia_ni           286 NVYMQLASEGRS---AKRRLLGESDVAAN----ALRSYTFVFPQYSSLEFVICGQLIDLA 
Bombyx_mori               272 NVYMQLASEGKS---AKRRLLGESDVAAN----ALRGYTFVFPQYSSLEFVICGQLVDLA 
Drosophila_melanogaster   361 GVYMQLNVNNR-----TPASFSQIGRQKS----AEADDAFIYPQFSGFEFVQTSQLLDLC 
Aedes_aegypti             339 GTYMQVNVTSRQMEMMHPHSVGACRKQQTTPSKPQLDESFVYPQFSGMEFAQTAQLIDLC 
 
Trichoplusia_ni           339 VLHVDVNLFAYSAVAAAAIAHAFTKELAIRVSGYNWDVLEPCWRWLAPFASVIRTEGSVC 
Bombyx_mori               325 VLHVDVNLFSYSAVAAAAIAHTYNRELAMRVSGYKWESLSECYTWLEPFARSLREAGAGG 
Drosophila_melanogaster   412 TLDVGMANYSYSVLAAAAISHTFSREMALRCSGLDWQVIQPCARWMEPFFRVIS--QKAP 
Aedes_aegypti             399 SLDVGLANFPYSVIAAAAVSHTFDRKTATSVSGLDWDAIAPCAKWMEPYFLVICDENEVS 
 
Trichoplusia_ni           399 VVRGGD-GEFLQAAGGLDLICPDVNLDESHRIQSHNVTLDMFDKVYQIMVEQQSV-TQTT 
Bombyx_mori               385 QVRAAD-GEFVQPAAALRHICPDINPDESHRIQQHNVTLDMFDKVYQAILEHS---SQHD 
Drosophila_melanogaster   470 YLQLNEQNEQVSNKFGLGLICPNIVTDDSHIIQTHTTTMDMYDEVLMAQDAAHAMRARIQ 
Aedes_aegypti             459 PLALLESNEQVKGSFGLAHVCPNLVSDSSHIIQTHSTSLDMFDRASLRREHLEVVACIIQ 
 
Trichoplusia_ni           457 SEAATSQESEHIYPPTPPASDHKS------------PKTPTTKTPSTRHLSPPPEARRLS 
Bombyx_mori               441 VCPSTSVDTDHIYPPTPPHSDHKS------------PKTPTTKTPSNRHEH----ELRIH 
Drosophila_melanogaster   530 ASPATA-LRAPESLLTPPASSHKPDEYLGDEGDETGARSGISSTTTCCNTAASNKGGKSS 
Aedes_aegypti             519 QEASPAPLLDPEGLLTPPASSRKS----------LDANNPLEVTNKLVNKT--------- 
 
Trichoplusia_ni           505 TE------------ 
Bombyx_mori               485 AD------------ 
Drosophila_melanogaster   589 SNNSVTSCSSRSNP 
Aedes_aegypti                      -------------- 
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accession # AB457002.2), Drosophila melanogaster (fruit fly; NCBI accession # 
NP_476960) and Aedes aegypti (mosquito; NCBI accession # EAT39115.1). The 
alignment was performed by ClustalW and coloring was performed by BOXSHADE. (b) 
Western blot results for T. ni CycE protein using rabbit anti-cyclin E against human 
(1:500 dilution). Lane 1: ladder; Lane 2: 5ug CycE; Lane 3: 10ug CycE; Lane 4: 5ug 
GFPuv (negative control). 
 
 
Manipulating CycE expression-effects on cell cycle and cell growth 
Up-regulation of CycE 
In order to confirm the protein is Cyclin E, we examined its function in T. ni cells.  
Specifically, the overexpression of cyclin E in mammalian cells leads to escape from cell 
cycle regulation and cancerous proliferation.  Similar phenomena have been reported in 
insect Drosophila cell cultures and adult flies [141, 142].  This proliferation leads to 
unchecked progression through G1 to S phase and a decrease of the G1 population.  Here, 
we characterize transcriptional and phenotypic changes of High Five cells associated with 
elevated CycE expression associated with transfection with pIB-TnCycE.  
As shown in Figure 4-2a (Land 4), mRNA transcription level increased 
significantly at 3 days post- transfection with pIB-TnCycE compared to pIB-EGFP or 
other controls.  In addition, it is also notable that the elevating CycE transcription with 
pIB-TnCycE treatment enhanced cell proliferation (Figure 4-2b), particularly at 3 days 
post-transfection.  Beyond three days, cell densities were close to the maximum 
supported by the growth medium.  Also as the CycE is expressed from the non-
replicating plasmids, the effects on regulating networks would be expected to be transient, 
particularly in rapid growth environments.  Even through the significant enhancement of 
cell growth, no obvious changes of cell cycle distribution were observed (Figure 4-2c).  It 
is interesting to note that cell cycle distribution for High-Five cells was found to be 
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heavily skewed towards the G2/M phases (G1:2.5%, S: 6.5%, G2/M: 65%, >4N: ~25%).  
Not surprisingly, CycE overexpression therefore led to no further distribution shift 
towards the G2/M phases (Figure 4-2c) even through significant enhancing on cell 
proliferation was observed.  This result lies in contrast to another industrially relevant 
insect cell line, Spodoptera frugiperda (Sf9) which under normal cell culture conditions 
exhibits 29% of the population in G1 (G1:29%, S: 33%, G2/M: 36%)[143].  In summary, 
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Figure 4-2  Effects of CycE up-regulation on cell physiology. Initially 0.2x106 cells/ml 
of suspension High Five cells were treated with Fugene + 4ug/ml pIB-TnCycE vector 
(for up-regulation), Fugene + 4ug/ml pIB-EGFP vector (control), and Fugene only 
(control). Cell samples were harvested at 3 day post transfection and subsequently 
measurement were conducted as followed. (a) mRNA transcriptional level by RT-PCR 
with actin primers (internal control); (b) time course measurement for cell proliferation 
was performed by using trypan blue; (c) cell cycle status was determined by flow 
cytometry using PI staining. 
 
 
Down-regulation of CycE 
In addition to up-regulation, experiments targeting CycE down-regulation were 
conducted. Phenotypic changes to cell cycle phase distribution and cell growth were 
characterized.  To down-regulate CycE, we synthesized dsRNA against T. ni CycE using 
the method by Hebert et al [144].  The selected dsTnCycE sequence as amplified was 
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~800 bp in length.  This relatively long form of dsTnCycE is thought to confer greater 
stability to dsRNA constructs leading to higher knockdown efficiency of the targeted 
gene [75].  We then performed studies using High-Five suspension cell cultures 
transfected with either dsTnCycE or a non-specific dsCAT control.  The mRNA level of 
CycE in the experimental population decreased significantly compared to the controls 
(Figure 4-3a), suggesting dsTnCycE treatment was successful.  Cell growth of CycE 
silenced populations was nearly abolished (4ug/ml)(Figure 4-3b).  This reduction of 
growth rate by knockdown was immediately observed only 1 day after transfection and 
persisted over the entire time course.  Analysis of investigating the effect of CycE 
knockdown on cell cycle phase distribution, we discovered a concentration dependent 
response to dsTnCycE (Figure 4-3c).  That is, peaks at G2/M phases (2N) were 
significantly shifted into G1 (1N) in a concentration dependent manner, while no shifts 
were seen for the dsCAT treatment and other controls.  Contrasting this to CycE 
upregulation suggests that wild type basal CycE abundance in High-Five cells is 
sufficient for ignoring the G1 to S phase checkpoint.  In summary, functional assays 
which support over-proliferation in the presence of high CycE and cell cycle-arrest in low 
CycE, correspond to physical characterization results.  That is, the sequence depicted in 































 Tn cell (control)







Fugene treated  
Control (T.  ni)
G1       G2/M  
mRNA transcriptional level  
Cell growth   




























Figure 4-3  Effects of CycE down-regulation on cell physiology. Suspension of High 
Five cells (0.2x106 cells/ml) were treated with Fugene + 4ug/ml dsTnCycE (for silencing), 
Fugene + 4ug/ml dsCAT (control), and Fugene only (control). (a) mRNA transcriptional 
level by RT-PCR with actin primers (internal control) was carried out at 3 day post 
transfection. (b) Time course measurement for cell proliferation was performed using 
trypan blue. (c) Dosage-dependent CycE silencing on cell cycle shifting was investigated 
by flow cytometry using PI staining at 3 day post transfection. 
 
 
Enhancing recombinant protein production-effects of CycE RNAi on baculovirus 
protein expression    
To investigate altering High-Five cell line productivity through cell cycle 
modulation, we utilized the baculovirus expression system, one of the most popular insect 
recombinant protein production platforms.  Briefly, High-Five cells adhered to 24-well 
plates were transfected with a broad range of dsTnCycE concentrations for 16 hours, 
followed by baculovirus (PPH-GFPuv ; GFPuv expression under the polyhedron promoter) 
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infection with various of MOI(0.1, 1, 10) for 4 days.  Subsequently, cells were then 
harvested and intra-cellular GFPuv expression was analyzed by flow cytometry.  The 
resultant fluorescence intensities were further integrated to determine the overall 
expression level of GFPuv.  As depicted in Figure 4-4, results displayed enhanced GFP 
expression up to 2.5-fold after treatment with dsTnCycE at high MOI (10).  However, at 
low MOI (0.1 and 1), the effects were not as significant, potentially due to the low 
expression level of GFPuv.  It was also notable that GFP expression peaked at 8 ug/ml 
dsTnCycE treatment and dropped significantly at 12 ug/ml, potentially indicating the 
range of dsTnCycE concentration at which cumulative phenotype changes adversely 
affect overall High-Five cell physiology.  Coincidently, similar CycE RNAi toxicity was 
also observed for Drosophila S2 cell line (~9 ug/ml) for optimized recombinant protein 
productivity [75].  In summary, we demonstrated the use of CycE RNAi to enhance 

























































Figure 4-4  Investigation of dosage-dependent dsTnCycE effect on intra-cellular 
productivity of adhesion High Five cells using baculovirus expression system. Cells were 
transfected with various concentrations of dsTnCycE (1ug/ml, 4ug/ml, 8ug/ml, and 
12ug/ml) using Fugene for 16 hours in prior to infection. Baculovirus AcMNPV that 
expresses GFPuv under the polyhedron promoter was utilized for infection with different 
MOI (0.1, 1, and 10). Cell samples were harvested and the fluorescence of intra-cellular 
GFPuv was measured by flow cytometry for protein productivity at 4 day post infection. 
 
 
Because High-Five cells efficiently secrete recombinant proteins into culture 
medium, we also tracked extracellular GFPuv.  Briefly, suspension cell cultures were 
transfected with various concentration of dsCycE for 16 hours, followed by baculovirus 
infection (MOI=10) for 2 to 7 days.  In order to establish the definition between intra-
cellular and extra-cellular GFP, 200 ul of each cell culture sample was harvested and 
centrifuged to separate the supernatant (the extracellular sample) and cell pellet.  The cell 
pellets were then lysed with 200ul CytoBuster TM lysis buffer, centrifuged to pellet cell 
debris, and the supernatant harvested to produce the intra-cellular sample.  Extracellular 
and intracellular GFP samples were measured by a plate reader and summed to derive a 
total product yield.  As shown in Figure 4-5a, the intra-cellular GFPuv of control samples 
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without dsCycE treatment increased significantly by day 3 then dropped thereafter; 
GFPuv expression of dsTnCycE treated cells, on the contrary, increased steadily over 
time, reaching a zenith at day 5.  Comparing the expression at 4 days post- infection, the 
dsCycE treated cells was roughly ~ 1.8-fold higher than mock infected cells, confirming 
the integrated FACS results from Figure 4-4.  Measurements of extra-cellular GFPuv 
(Figure 4-5b), however, showed a converse outcome where supernatants from control 
wells had higher GFPuv than treatment wells.  Apparently, the dsRNA reduced the 
secretion rate of GFPuv in transfected cells.  Yet, the overall production of GFPuv 
(Figure 4-5c) derived by combining intra-cellular and extra-cellular RFU values, resulted 
in a nearly 1.5-fold increase.     
In summary, a cell cycle arrest strategy using dsTnCycE successfully enhanced 
the cell productivity.  We speculate two potential reasons.  First, as mentioned above, 
dsRNA treatment prolonged the GFPuv production window to 5th day post-infection.  
This is atypical of baculovirus production where the peak productivity normally appears 
in 2 to 4 days.  Second, the secretion of GFPuv into the medium was reduced, which 
might indicate the baculovirus lytic process from the host was suppressed.  This 
observation is partially supported by Braunagel et al., (1998) [143] who showed that sf9 
cells pre-arrested in G1 and S phases prior to baculovirus infection do not affect viral 
DNA replication, but that progeny virus assembly and maturation, e.g. occlusion-derived 
virus, become abnormal.  Further investigations would be necessary to resolve the 




























































Figure 4-5  Effects of dosage-dependent dsTnCycE on intra- and extra-cellular 
productivity of suspension High Five cells using baculovirus expression system. Cells 
were transfected with various concentrations of dsTnCycE (2ug/ml, 4ug/ml, 8ug/ml, and 
12ug/ml) using Fugene for 16 hours in prior to infection. Same baculovirus which 
produces GFPuv was utilized for infection with MOI 10. For preparing samples, cells for 
extra-cellular GFPuv were prepared by collecting the supernatant form the infected cell 
medium; the cell pellets from the infected cell medium was lysed by cytobuster lysis 
buffer and the supernatant was collected as the intra-cellular GFPuv. Both intra- and extra-
cellular GFPuv intensities were measured by a plate reader from 2 to 7 day post infection 
and represented in (a) and (b) respectively. Overall productivity, as shown in (c), was 





We have successfully identified the complete cyclin E cDNA sequence of T. ni 
and characterized the recombinant CycE through physical and functional analyses.  We 
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have observed that the up-regulation of CycE actively facilitated cell growth without 
perturbing the cell cycle distribution; meanwhile, down-regulation of CycE expression 
through in vitro dsTnCycE caused cell cycle arrest at G1 phase and inhibited cell growth 
significantly.  Finally, we demonstrated the concentration-dependent dsTnCycE silencing 
effect on enhancing both the intra- and extra-cellular GFPuv production of T. ni cell 
culture via the baculovirus expression system.  An optimal concentration of RNAi for 
protein productivity was identified.     
The RNAi strategy for cell cycle regulation, unlike some procedures using 
chemicals, is biological based and metabolizable for cells, which might add further 
benefit by extending cell longevity and productivity.  This approach which targets a 
global condition using a simple molecular-based switch holds great promise to enhance 




Chapter 5. Summary 
 Assembling of antibodies and antigens through protein G 5.1.
biofabrication   
In Chapter 2, we engineered  protein G, an IgG binding domain, with an enzyme-
activatable pentatyrosine “pro-tag” that allows covalent coupling to the pH stimuli-
responsive biopolymer, chitosan, which is spatially addressed through electro-signaling. 
Different configurations or formats, such as multiwell plates, micropatterned electrodes, 
and fiber networks are demonstrated.  We assembled both HG3T and antibodies, finding 
assembly in a linear fashion so that quantitative assessment of antibodies and antigens 
became feasible.  This biofabrication approach provides bottom-up hierarchical assembly 
of functional supramolecular structures that could be designed to facilitate integration 
into devices.  
 
 Developing a smart bacterial switch device with targeting, sensing, 5.2.
and switching capabilities  
We engineered an E. coli K-12 W3110 with a genetic circuit that endows it with 
targeting, sensing and switching capabilities.  The protein G is displayed on the outer 
membrane of the bacteria which allows for flexible targeting through antibody-antigen 
interaction.  In addition, we created a cell-based biological switch that was activated 
based on surface receptor density on mammalian cells.  That is, we found that the 
accumulation of bacteria at the target surface triggered a “switch” in response to EGFR 
density on a mammalian cell model.  This serves as a phenotype focusing system as it 
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maintains the switch in an “off” state until the desired threshold is reached.  We believe 
this switch could potentially be exploited via synthetic biology tool for the synthesis and 
delivery of human therapeutics.  
   
 Exploiting RNAi to control cell cycle/cell growth of eukaryotic insect 5.3.
cell for enhancing recombinant protein productivity  
We employed a metabolic engineering approach to “tune” the cell cycle to 
overcome checkpoint processes.  This facilitated faster cell growth and depending on the 
added concentration, arrested cells at a high productivity phase for recombinant protein 
synthesis.  To do this, we identified the complete cyclin E (CycE) sequence from 
industrially relevant, Trichoplusia ni genomes (cDNA).  We then then synthesized T. ni 
CycE specific RNAi to test CycE suppression.  By knocking down (through RNAi) and 
overexpressing CycE (on an expression plasmid) gene expression, we successfully 
lowered and raised cell growth, respectively.  We also investigated the dose-dependent 
effects of dsCycE on recombinant protein production using the baculovirus expression 






 Future directions 5.4.
 Incorporating of invasin protein into the QS switch for bacteria targeting and 5.4.1.
invasion     
We demonstrated that we could create bacteria that would recognize EGFR 
receptor densities on the surface of cancer cell lines.  Upon reaching a threshold density, 
the cells produced DsRed.  It would be quite interesting to have the cells produce a 
peptide on the outer surface to facilitate its direct attachment to the cell surface and 
subsequent cargo delivery.  We have hypothesized that invasin [145] could provide this 
function. Grillot-Courvalin et al. (1998) [145] showed Inter-kingdom gene transfer from 
E. coli K12 bacteria to mammalian cells by using invasin, an invasion promoting protein 
derived from Yersinia pseudotuberculosis that triggers endocytosis.  Many follow-up 
gene therapy applications utilizing the same bacteria carrier have been reported [146-148].  
This invasin delivery approach is powerful in terms of delivery efficiency; but lacks 
targeting specificity.  We therefore seek to combine specific targeting (through antibody) 
and cargo delivery (through invasin triggered endocytosis) based upon the bacteria switch 
we have created.  Specifically, we could replace the DsRed model protein with invasin in 
our genetic circuitry, which would allow the bacteria to decide whether or not to invade 
the mammalian cell on which they have docked based on the targeting density.  We 
envision this new invasin switch would be beneficial in some therapeutic cases by 
providing a means of tightly controllable, high threshold, low background response in 





 Using RNAi as a cell proliferation control agent in bacteria cancer therapeutics  5.4.2.
Using an RNAi approach, we have demonstrated the competence of cell cycle 
regulation in order to block aberrant cell growth arising from skewed cell cycle phase 
distributions.  RNAi based cancer therapies are already under development [149-151].  
Xiang et al. (2006) [152] demonstrated the feasibility of using bacteria to synthesize and 
carry short hairpin RNA to perform gene silencing in mammalian cell and mice systems.  
Here, we would seek to exploit bacteria as a targeted vector to deliver RNAi to 
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